A Dual‐Bioresponsive and Programmable Microneedle Matrix as a Bioinspired Coupler for Orchestrating Diabetic Bone Regeneration Authors: Yu Wang, Rui Chen, Yu Chen, Haowen Lu, Yuchen Qian, Zhiheng Gao, Zheming Shen, Xiaofei Zheng, Huilin Yang, Jun Zou, Yusen Qiao Published: 2026 ABSTRACT ABSTRACTDiabetic bone repair is impaired by a microenvironment characterized by heightened susceptibility to infection and persistent inflammation. This study presents a dissolvable, dual‐responsive (to glutathione and gelatinase) microneedle patch (CGF/PP@MN) for spatiotemporally controlled therapy. The system features a GelMA hydrogel matrix encapsulating Concentrated Growth Factors (CGF) within its core, while its surface is functionalized with a glutathione‐reactive anti‐inflammatory peptide (pro‐AIP) and a gelatinase‐cleavable antimicrobial peptide (pro‐AMP). This spatial design enables a sequential, pathology‐triggered release cascade: upon insertion, pro‐AMPs are first cleaved in the presence of bacterial gelatinase to eradicate biofilms; subsequently, the elevated glutathione concentration activates pro‐AIPs to mitigate inflammation and promote M2 macrophage polarization, thereby remodeling the hostile immune niche. Finally, the sustained release of CGF from the hydrogel core drives vascularization and osteogenesis. This platform demonstrates precise temporal alignment with endogenous healing, excellent biocompatibility, and robust bioactivity in vitro. In a diabetic bone defect model, it significantly enhanced wound healing, attenuated inflammation, promoted robust bone regeneration, and improved overall repair outcomes. This work provides a novel combinatorial strategy for immunomodulation and regenerative repair of diabetic bone defects.Keywords: concentrated growth factors (CGF), diabetic bone regeneration, dual‐responsive microneedle, immunomodulation, osteogenesis, spatiotemporal drug delivery Introduction The impaired healing of bone defects in diabetes presents a substantial clinical challenge, primarily because it disrupts a precisely coordinated temporal program governing physiological bone regeneration [1]. This program depends on well‐orchestrated immune‐osteogenic coupling (osteoimmunology), wherein an initial inflammatory phase transitions seamlessly into a pro‐regenerative state that promotes angiogenesis and osteogenesis [2, 3, 4, 5, 6]. Diabetes acts as a biological disruptor of this coupling. A hyperglycemic microenvironment, characterized by persistent oxidative stress and accumulation of advanced glycation end products (AGEs), traps the local immune response in a chronic pro‐inflammatory state [7, 8]. This is epitomized by a failure of macrophages to switch from an M1 to an M2 phenotype. Such aberrant immune polarization directly suppresses the osteogenic function of bone marrow mesenchymal stem cells (BMSCs) and impairs vascularization [5, 9, 10]. Consequently, a self‐perpetuating cycle emerges, where unresolved inflammation and compromised regeneration reinforce each other, effectively dismantling the sequential logic of bone repair and stalling the process in a pathological, non‐healing state [11, 12, 13]. Recent advances in biomaterial design offer multifaceted strategies to intervene in this complex process. These strategies span from constructing multifunctional coatings on implants to enhance corrosion resistance, antibacterial properties, and direct osteogenic activity; developing smart, shape‐adaptive hydrogels that conform to irregular defects and provide sustained release of osteoinductive factors; to employing immune‐engineering principles, particularly with electrospun fibers, to actively modulate the local immune microenvironment toward a pro‐regenerative phenotype [14]. Furthermore, biomimetic approaches are being explored to address specialized regeneration needs, such as designing hydrogels that replicate the growth plate's structure and hypoxic niche to promote chondrogenic differentiation and prevent aberrant bone formation, thereby restoring longitudinal bone growth. Collectively, these diverse approaches underscore a paradigm shift toward creating intelligent, multifunctional biomaterials that not only provide structural support but also dynamically interact with the biological system to orchestrate the sequential stages of bone healing [15, 16, 17, 18, 19, 20]. Current ‘smart’ biomaterial strategies show critical limitations in addressing this dysregulated sequencing. Most systems are designed for single‐point responsiveness, for example, solely to pH or reactive oxygen species, offering isolated solutions such as antibacterial or anti‐inflammatory effects [10, 21, 22, 23, 24, 25]. For example, polysaccharide‐based hydrogel dressings that respond solely to pH variations in chronic wounds [26], or nanocarriers that rely exclusively on pH‐triggered charge reversal for gene delivery [27]. Similarly, a significant body of research has concentrated on developing polymers or hydrogels that are primarily responsive to the levels of reactive oxygen species (ROS), for applications in antioxidation or targeted delivery [28, 29]. They lack the capacity for continuous sensing and dynamic feedback throughout the entire bone regeneration cascade. This inability to horizontally connect individual repair stages‐for example, infection control, inflammation resolution, angiogenesis, and osteogenesis‐results in a disjointed and inefficient repair process [30, 31, 32, 33, 34, 35]. Consequently, they fail to achieve genuine temporal regulation and cannot rebuild the self‐sustaining, orderly progression of healing [23, 36]. This fundamental shortcoming underscores the urgent need for a new strategic framework capable of holistic sequential reprogramming. To overcome the limitations of current strategies, this study proposes a novel hierarchically intelligent framework aiming to achieve a paradigm shift from single‐point responsiveness to vertical integration across pathological dysregulation (Figure 1). The core of this framework is the construction of an adaptive system capable of dynamically sensing, interpreting, and intervening in the diabetic bone microenvironment, thereby reconstructing the disrupted chronological logic of regeneration [37, 38]. Microneedle technology, by virtue of its exceptional capabilities in targeted delivery and sustained release, provides an ideal platform for achieving this goal. It not only directly targets infected tissues to enhance antibacterial efficacy, but its multilayer structure also allows for programmable synergistic or sequential release of multiple functions, including antibacterial, antioxidant, and proangiogenic offerings, offering a crucial technological vehicle for coordinating the complex regeneration cascade [39, 40, 41, 42, 43, 44, 45]. Schematic illustration of a spatiotemporally programmable microneedle matrix for orchestrating diabetic bone regeneration. This diagram summarizes (A) the MN architecture and underlying mechanism for responsive, sequential release of cargo payloads; (B) the multifaceted therapeutic mechanisms, encompassing immunomodulation via macrophage polarization to an M2 phenotype alongside potent antibacterial efficacy through bacterial membrane disruption; and (C) the coordinated healing cascade following application to a diabetic bone defect, which progresses from initial anti‐inflammatory and antibacterial stages to robust angiogenesis and osteogenesis, culminating in functional bone repair. Concentrated Growth Factor CGF as a novel autologous biomaterial, provides a rich bioactive foundation for regenerative repair due to its potent abilities to promote osteogenesis, angiogenesis, and induce M2 macrophage polarization [46, 47, 48]. Based on this, we constructed a GelMA‐based microneedle patch. Its core encapsulates CGF while its surface is grafted via dopamine mediation with a glutathione‐responsive anti‐inflammatory peptide and a gelatinase‐responsive antimicrobial peptide. This design enables the spatiotemporally controlled release of CGF coupled with intelligent antibacterial and immunomodulatory functions (Figure 2A). Comprehensive characterization of the spatiotemporally programmable microneedle (MN) matrices (A) schematic of the MN fabrication process; (B) illustration of Concentrated Growth Factors (CGF) extraction; (C) photographic documentation of laboratory‐isolated CGF gel blocks (a, b) and macroscopic views of blank MNs (c) versus CGF/PP@MN (d); (D) high‐magnification SEM images revealing the internal porous structure of blank MNs (a, b) and CGF distribution within CGF/PP@MN; Scale bar = 10µm(a,c); Scale bar = 2µm(b,d). (E‐G) schematic of the core‐shell MN construction and surface modification protocol; (H) mechanical property characterization setup; (I) SEM micrographs comparing surface morphology of plain MN, CGF@MN, and CGF/PP@MN; Scale bar = 50µm (J) optical images capturing MN structural integrity pre‐ and post‐mechanical testing; Scale bar = 500µm (K‐N) corresponding force‐displacement profiles for MN, CGF@MN, and CGF/PP@MN. Statistical significance was determined by one‐way ANOVA with Tukey's post hoc test; p < 0.01,* p < 0.001 versus the MN group; ##p < 0.01 versus the CGF@MN group. Our work establishes a therapeutic platform that advances the field through integrated innovations across multiple levels. At the core of its design is a dual‐responsive microneedle system capable of sensing and reacting to the pathological diabetic microenvironment, thereby enabling intelligent, spatiotemporally controlled release of therapeutic agents. This material innovation allows for the first time the sequential orchestration of three distinct yet interdependent biological functions—effective antimicrobial action, proactive immune remodeling, and potent osteogenesis—within a single, coordinated therapeutic intervention. Transcending a conventional combinatorial approach, this strategy embodies a “vertically integrated” therapeutic paradigm. It is designed not merely to deliver factors but to actively reprogram the dysregulated chronology of diabetic bone healing, offering a coherent framework that translates complex osteoimmunological principles into a targeted and intelligent biomaterial‐based therapy. Results and Discussion Preparation and Characterization of CGF In this study, CGF were extracted from venous blood (8 mL) collected from SD (Sprague Dawley) rats using blood collection tubes without anticoagulants. The blood was immediately centrifuged (Medifuge MF200; Silfradent srl, Forlì, Italy) under a programmed protocol: 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, and 3 min at 3000 rpm. This process yielded three distinct layers: a top serum layer, a middle fibrin‐rich CGF gel, and a bottom erythrocyte‐platelet layer. The middle CGF gel layer, along with adjacent red blood cells, was carefully retained for further analysis (Figure 2B‐C). We conducted a systematic evaluation of three prevalent liquid CGF extraction methods, as documented in the literature, to assess their impact on the retention efficiency of active components [49, 50]. The quantitative data indicated that Method 2, which involves freeze‐thaw cycling coupled with centrifugation and filtration, resulted in the highest CGF concentration, with an average concentration of approximately 32 pg/mL. This was significantly higher than the concentrations obtained using Method 3 (homogenization followed by centrifugation and freezing, average concentration approximately 27.50 pg/mL) and Method 1 (mechanical compression separation, average concentration approximately 20.89 pg/mL) (Figure 3C). These findings demonstrate that Method 2 is superior in maximizing the extraction of bioactive components from CGF. Consequently, this study adopted Method 2 as the standardized protocol for liquid CGF extraction to ensure consistency in CGF content and bioactivity in subsequent experiments. The concentration of TGF‐β1, as a representative component of Concentrated Growth Factor (CGF), was quantified using a commercial rat TGF‐β1 ELISA kit according to the manufacturer's instructions. Absorbance was measured at 450 nm, and sample concentrations were calculated based on a standard curve with concentrations ranging from 0 to 32 pg/mL (Figure 3F). The standard curve exhibited a high correlation coefficient (R = 0.9956), indicating excellent assay reliability. Material characterization and release profiles (A‐B) Computer‐simulated molecular structures and chemical formulae of pro‐AMP and pro‐AIP; (C) Quantitative comparison of TGF‑β1 extraction efficiency across three methodologies, with Method 2 achieving optimal concentration (32.12 pg/mL); Data are presented as mean ± SD (n = 3 independent experiments); *** p < 0.001 vs. Method 1 and Method 3 by one‐way ANOVA with Tukey's post hoc test. (D‐E) XPS analysis demonstrating C1s and O1s peak intensity variations among MN, pro‐AIP@MN, pro‐AMP@MN, and PP@MN; (F) ELISA‐based concentration quantification of TGF‑β1 showing a linear correlation (R = 0.9956); (G) FTIR spectra revealing characteristic peak disappearance at 1403 cm− 1 in peptide‐loaded MNs, confirming carboxylate‐amine crosslinking between GelMA and bioactive peptides, with emergent amide I band at 1630 cm− 1 in PP@MN indicating successful peptide integration; (H) XRD patterns displaying preserved secondary structures with characteristic diffraction peaks at 14.8°/17.9° (α‐helix) for pro‐AMP and 22.6°/42.7° (β‐sheet) for pro‐AIP in composite MNs; (I) Schematic of stimulus‐responsive peptide release mechanism; (J‐K) Cumulative 24h peptide release under 20µM/200µM GSH conditions; (L) Baseline release profile in PBS control; (M‐N) Enzymatically‐triggered release kinetics under 1µm/10µm gelatinase exposure. All release data are presented as mean ± SD (n = 4 independent replicates per time point). Preparation and Characterization of CGF@MN Herein, we developed a core–shell structured hydrogel microneedle system utilizing gelatin methacryloyl (GelMA) as the primary matrix, which was loaded with concentrated growth factors (CGF) (Figure 2A). We employed a custom‐fabricated PDMS mold to engineer CGF@MN patches via a micromolding technique. A homogeneous blend of liquid GelMA solution and CGF at a concentration of 100 mg/mL was prepared prior to processing (Figure 2F). The resulting patch measures 24 mm in diameter and integrates an array of 144 microneedles, each featuring a conical geometry with a height of approximately 800 µm and a base width of 200 µm. The morphological and structural integrity of the microneedles was verified using scanning electron microscopy (SEM) (Figure 2I). To eliminate solvent artifacts, the patches underwent vacuum freeze‐drying prior to analysis. Subsequently, the microneedles were longitudinally sectioned, and high‐resolution SEM imaging was performed. This analysis confirmed the presence of a highly porous internal architecture and the successful incorporation and uniform distribution of CGF throughout the microneedle matrix (Figure 2D). Preparation and Characterization of Pro‐AMP/AIP Despite the promising anti‐infective and immunomodulatory properties of novel peptide‐based drugs, their clinical translation is significantly hampered by inherent limitations such as high proteolytic susceptibility and structural instability, leading to short half‐lives and low bioavailability that compromise pharmacokinetic performance [51, 52]. By incorporating responsive elements, peptides can undergo conformational changes under specific environmental conditions, enabling controlled drug release and targeted delivery. Compared to conventional therapeutics, such responsive systems exhibit superior performance within complex physiological environments [53, 54, 55]. In this study, we selected the antimicrobial peptide BRBR‐NH2 [56] and the immunomodulatory peptide mast‐MO [57] as the functional components of the pro‐antimicrobial peptide (pro‐AMP) and pro‐immunomodulatory peptide (pro‐AIP) systems, respectively. To achieve specific antibacterial and anti‐inflammatory responses, each peptide was conjugated with distinct cleavable linkers: an enzyme‐responsive sequence, Pro‐Leu‐Gly‐Val‐Arg‐Gly (PLGVRG), was attached to BRBR‐NH2, while a glutathione (GSH)‐responsive disulfide bond (‐S‐S‐) was incorporated into the structure of mast‐MO (Figure 3A,B). The selection of these specific linkers was driven by the distinct biochemical landscapes of the target microenvironments. For the pro‐AMP, the PLGVRG sequence is a well‐characterized, highly specific substrate for matrix metalloproteinase‐2/9 (gelatinase), which is overexpressed by activated neutrophils and macrophages at infection sites, with reported concentrations reaching up to 10 µm in pathological conditions. This ensures precise, on‐demand activation primarily in infected bone defects while minimizing off‐target cleavage. For the pro‐AIP, the disulfide bond leverages the dramatic reducing potential within inflamed cells, where intracellular GSH concentrations (1–10 mm) are 100 to 1000‐fold higher than extracellular levels. This steep gradient facilitates selective intracellular release of mast‐MO upon uptake by pro‐inflammatory immune cells, enabling targeted immunomodulation. The synthesis of these precise peptide constructs, documented in the supporting information, confirms the successful incorporation of the PLGVRG linker into pro‐AMP and the formation of the intermolecular disulfide bond in pro‐AIP, underscoring the feasibility of this rational design approach. The PLGVRG linker can be cleaved by gelatinase to generate the hydrophobic fragment P18‐PLG. During bacterial, viral, or fungal infection, neutrophils are activated and release substantial amounts of gelatinase to combat pathogens [58, 59]. Thus, under infectious conditions with elevated gelatinase levels, the PLGVRG linker undergoes enzymatic cleavage, resulting in the responsive release of the antimicrobial peptide BRBR‐NH2. In inflammatory environments, glutathione (GSH) concentrations are significantly elevated. This pronounced differential in GSH levels between intracellular and extracellular milieus has been widely exploited in the design of stimulus‐responsive therapeutic systems for controlled intracellular drug delivery [60, 61, 62, 63]. Among these strategies, the disulfide bond (‐S‐S‐) can be cleaved via thiol‐disulfide exchange reactions mediated by intracellular GSH [64, 65], thereby enabling responsive release of the immunomodulatory peptide mast‐MO. The synthetic peptide pro‐AMP, with a molecular weight of 2320.64 Da and a purity of 97.92%, was confirmed by ESI‐MS, showing prominent ions corresponding to [M+4H]3+ and [M+3H]4+ charge states. Its structure incorporates an enzyme‐responsive PLGVRG sequence, designed for gelatinase‐triggered cleavage (Figures S1 and S2). Similarly, peptide pro‐AIP (MW: 3002.75 Da, purity: 97.61%) exhibited ESI‐MS signals consistent with its expected mass, including [M+3H]3+ and [M+5H]5+ ions. This peptide features an immunomodulatory FLPIII motif and a redox‐sensitive disulfide bond, enabling glutathione‐responsive release in reducing environments (Figures S3 and S4). Both peptides contain N‐ and C‐terminal DOPA modifications and TFA as counter ions, supporting their potential use in controlled drug delivery systems. Preparation and Characterization of CGF/PP@MN The synthesized pro‐AMP and pro‐AIP were non‐covalently conjugated and immobilized onto the microneedle surface to form the CGF/PP@MN patch (Figure 2A,E‐G). The loading amount of each peptide was approximately 100 µg per patch. The peptide loading efficiency was systematically characterized using XPS (Figure 3D,E), XRD (Figure 3H), and FTIR (Figure 3G) analyses by comparing MN patches without CGF, those loaded individually with pro‐AMP or pro‐AIP, and the complete CGF/PP@MN patch. X‐ray diffraction (XRD) analysis revealed that the composite patch retained all characteristic diffraction peaks of its individual components. Peaks at 14.8° and 17.9° are associated with the α‐helical structure of the antimicrobial peptide, while those at 22.6° and 42.7° correspond to β‐sheet features of the anti‐inflammatory peptide. The persistence of these signals—without diminution or disappearance—confirms that both peptides maintained their structural integrity upon incorporation into the GelMA matrix. The observable changes in peak intensities suggest non‐covalent interactions such as hydrogen bonding or van der Waals forces between the peptides and GelMA, indicating integration beyond simple physical mixing. Fourier‐transform infrared (FTIR) spectroscopy provided further evidence of successful conjugation. The disappearance of the ‐COO‐ stretching vibration at 1403 cm− 1 indicates cross‐linking between carboxyl groups on GelMA and free amino groups from the peptides. Concurrent enhancement of the amide I band at 1630 cm− 1 and the emergence of a new C‐O stretching vibration at 1009 cm− 1 suggest molecular interactions and possible complex formation between the peptides and the hydrogel matrix. X‐ray photoelectron spectroscopy (XPS) analysis further strengthened these findings and provided direct evidence of intermolecular interactions. The C 1s and O 1s spectra not only confirmed the presence of peptide backbone elements and oxygen‐containing functional groups but also revealed measurable chemical shifts. As shown in Figure D, compared to pure GelMA MN, the peptide‐loaded samples (Pro‐AMP@MN, Pro‐AIP@MN, PP@MN) exhibited a small but consistent shift (∼0.2–0.4 eV) toward higher binding energy for the characteristic peaks corresponding to C‐O/C‐N bonds (∼286.0–286.5 eV) and C═O/O─C─O bonds (∼288.0–288.5 eV) in the C 1s spectra. This positive shift typically indicates a decrease in the electron cloud density around the carbon atoms. Similarly, in the O 1s spectra (Figure E), the O = C (∼531.4 eV) and O‐C (∼532.8 eV) peaks of the peptide‐loaded samples showed analogous slight shifts toward higher binding energy. These systematic peak shifts strongly indicate significant non‐covalent interactions, such as hydrogen bond formation (particularly between the amide bonds/amino groups of the peptides and the carboxyl/hydroxyl groups of GelMA), between the peptides and the GelMA matrix. This interaction alters the local electronic environment of the involved atoms, manifesting as binding energy shifts in the XPS spectra. This corroborates the peak position changes and intensity variations observed in the FTIR data, collectively confirming that the peptides are not merely physically mixed but are stably integrated into the GelMA hydrogel network via intermolecular forces. Collectively, these results verify the effective and stable incorporation of pro‐AMP and pro‐AIP into the CGF/PP@MN system, affirming the successful fabrication of a multifunctional MN patch capable of responsive antibacterial and immunomodulatory functions. In Vitro Drug Release Kinetics The release profiles of pro‐AMP and pro‐AIP from microneedle (MN) patches were quantitatively assessed using LC‐MS/MS under simulated physiological and stimulus‐rich conditions (Figure 3I). A clear stimulus‐responsive release pattern was confirmed for each peptide. In the presence of gelatinase at concentrations of 1 µM and 10 µM, a substantial increase in cumulative release was observed over 24 h. For example, treatment with 10 µM gelatinase resulted in a released concentration of approximately 3 ng/mL at 6 h and 12 ng/mL at 24 h (Figure 3J,K), which was significantly higher than the minimal release observed in PBS controls, such as 2.58 ng/mL at 24 h (Figure 3L). This pronounced enzyme‐dependent release confirms that pro‐AMP is selectively liberated in response to gelatinase, supporting its proposed function in targeting infection microenvironments. Under high glutathione (GSH) concentrations of 20 and 200 µm, pro‐AIP exhibited clear concentration‐dependent release kinetics. At 20 µm GSH, the release of pro‐AIP continued to rise over 24 h, reaching nearly 9 ng/mL at the 24‐h time point, which was markedly higher than that in the PBS control group (3.96 ng/mL at 24 h), indicating its responsiveness to physiologically relevant GSH levels. Notably, under a highly reductive microenvironment simulated with 200 µm GSH, the release profile of pro‐AIP showed more pronounced characteristics: its cumulative release remained higher than that of pro‐AMP throughout the observation period, and an accelerated release trend was observed between 12 and 24 h. This demonstrates that a high‐GSH environment can more rapidly trigger disulfide‐bond cleavage, thereby accelerating the release of pro‐AIP.(Figure 3M,N). This behavior indicates redox‐sensitive cleavage of the disulfide bond without evidence of premature leakage. Both peptides showed minimal undesired leakage in PBS throughout the 24 h period (e.g.,≤3.96 ng/mL for pro‐AIP), underscoring the stability of their non‐covalent incorporation into the MN matrix. No burst release was observed, suggesting the absence of superficial adsorption or physical mixing. These results robustly validate the design of two distinct stimulus‐responsive mechanisms, each selectively activated by a specific biological trigger. The peptide pro‐AMP demonstrates clear responsiveness to gelatinase, while pro‐AIP exhibits high sensitivity to glutathione (GSH). Collectively, these findings confirm the effective non‐covalent incorporation of both peptides into the microneedle patches and underscore their capability for on‐demand release within complex biological milieus. The in vitro release study in this work successfully validated the core functionalities of “sequential release” and “enzyme concentration‐responsiveness” of the delivery system. It is important to note that the standardized 24‐h release test was designed to elucidate the release mechanism and triggering logic, not to predict the final total drug delivery amount in vivo. For treating chronic biofilm infections, the key to efficacy lies in the sustained, targeted drug release and local accumulation triggered by the infection microenvironment. Under in vivo conditions, the persistently present matrix metalloproteinases (MMPs) at the biofilm site will provide a long‐term, dynamic release stimulus for this system, enabling the continuous enrichment of the antimicrobial peptide at the target locale. Its accumulated concentration is highly likely to reach and exceed the effective inhibitory concentration (MIC) [66] against the target pathogen. This inference is corroborated by subsequent functional assays: the responsive microspheres loaded with the antimicrobial peptide exhibited superior eradication efficacy against mature biofilms in vitro (Figure 4), and significantly promoted healing while reducing bacterial burden in a murine infected skin wound model (Figures S10 and S11). These results collectively indicate that, through its unique responsive release design, our delivery system can achieve pharmacologically meaningful drug delivery and antibacterial efficacy in vivo. In vitro antibacterial performance evaluation of functionalized microneedle patches. (A) Live/dead fluorescence staining images of bacteria after 24 h of co‐culture with different MN formulations. Green fluorescence indicates live bacteria (SYTO‐9 staining), and red fluorescence indicates dead bacteria (propidium iodide staining). Scale bar: 50 µm. (B–E) Quantitative analysis of antibacterial rates for S. aureus (B) and E. coli (C), and bacterial survival rates for S. aureus (D) and E. coli (E). Data are presented as mean ± SD (n = 6); ** p < 0.01 vs. control group. (F–G) Comparison of antibacterial rates among different membrane‐modified groups for S. aureus (F) and E. coli (G). (H–I) Plate coating assay and colony counting results: (I) Photographs of bacterial colonies on agar plates after treatment; (H, J) Corresponding quantitative analysis of colony‐forming units (CFUs). Data are presented as mean ± SD (n = 6); **p < 0.01, ***p < 0.001 vs. control group by one‐way ANOVA with Dunnett's post hoc test. Time‐dependent antibacterial kinetics showing counts of viable bacteria (CFUs) for E. coli and S. aureus over 24 h. The CGF/PP@MN group exhibited the strongest antibacterial activity, with nearly complete inhibition of bacterial growth, demonstrating synergistic effects between the bioactive components. Statistical significance was determined by one‐way ANOVA followed by Tukey's multiple comparisons test; *** p < 0.001, ** p < 0.01 vs. indicated groups (n = 6). Mechanical Properties of MN Patch The mechanical properties of the different microneedle (MN) formulations were systematically evaluated through compression testing (Figure 2H), with the resulting force–displacement curves provided. The experimental groups were designated as follows: MN, CGF@MN, and CGF/PP@MN. All groups exhibited similar mechanical behavior, characterized by a linear elastic deformation phase followed by a rapid drop after reaching the maximum force, indicative of typical brittle fracture mechanics. The maximum failure load for all groups reached approximately 3.0 N, demonstrating high mechanical strength suitable for skin penetration (Figure 2K‐N). Notably, the presence of CGF and the subsequent non‐covalent conjugation of peptides did not induce significant alterations in the mechanical performance. The curves largely overlapped during the elastic phase, and the peak forces showed no statistically significant differences among groups, confirming that the surface modifications did not compromise the structural integrity or mechanical robustness of the microneedles (Figure 2M). The failure loads of all MN formulations substantially exceeded the minimum force required to penetrate human skin (0.1 N) [67], often by more than two orders of magnitude. This substantial safety margin ensures reliable skin insertion without mechanical failure, supporting their potential for practical transdermal applications. The mechanical analysis confirms that both the incorporation of CGF and the functionalization with peptides via non‐covalent strategies preserve the mechanical properties of the microneedles, affirming their suitability for use in advanced drug delivery systems. In Vitro Antibacterial Activity Based on colony formation assays and bacterial live/dead staining results, the engineered material demonstrated high efficiency and specific antibacterial performance. Colony counting confirmed that all functionalized groups (PP@MN, CGF@MN, CGF/PP@MN) exhibited significant antibacterial activity against both Gram‐negative E. coli and Gram‐positive S. aureus (p < 0.01). Among them, the CGF/PP@MN group showed the most potent effect (Figure 4I), achieving antibacterial rates of 99.84% against E. coli and 99.36% against S. aureus (Figure 4F‐J), resulting in near‐complete bactericidal efficacy. The efficacy trend followed: CGF/PP@MN > PP@MN > CGF@MN > MN, demonstrating a synergistic effect of the peptide combination. Live/dead staining under confocal laser scanning microscopy further elucidated the underlying mechanism: extensive red fluorescence, indicative of dead bacteria, was observed in groups treated with PP@MN, CGF@MN, and CGF/PP@MN (Figure 4A). Quantitative analysis using LAS X software revealed a dramatic decrease in bacterial survival rates. After CGF/PP@MN treatment, only 0.69% of E. coli and 0.86% of S. aureus remained viable, compared to over 99% viability in the blank control (Figure 4B‐E). This corresponds to antibacterial rates of 99.31% against E. coli and 99.14% against S. aureus, consistent with the colony counting results. The key mechanism involves the enzymatically responsive rapid release of lytic peptides, which selectively disrupt bacterial membrane integrity. This targeted action leads to rapid cell lysis and metabolic inactivation, with a more pronounced effect against S. aureus due to its lack of an outer membrane. The intelligent release system ensures precise and efficient bactericidal activity. Through RNA sequencing, we elucidated the triple synergistic mechanism of CGF/PP@MN against S. aureus, involving “Structural Disruption – Metabolic Inhibition – Dysregulation of Genetic Programs”. PCA (Figure 5A) and sample correlation heatmaps (Figure 5B) demonstrated global transcriptomic reprogramming, confirming the comprehensiveness of this mechanism. At the structural level, the volcano plot (Figure 5C) showed significant upregulation of numerous cell wall synthesis‐related genes, indicating direct physical damage to cell wall integrity and the triggering of emergency repair responses. GO enrichment in Figure S5 further confirmed the significant activation of cell wall biosynthesis processes, while PPI network analysis (Figure S7) revealed the central role of key enzymes in cell wall synthesis within the protein interaction network. Systemic Impact of CGF/PP@MN on the Staphylococcus aureus Transcriptome and Core Antibacterial Mechanisms. (A) PCA analysis reveals clear separation between treated and control groups along PC1 (67.2%) and PC2 (18.5%). (B) The sample correlation heatmap shows significantly higher intra‐group correlation (r > 0.95) than inter‐group correlation (r < 0.6). Analysis based on n = 3 biological replicates per group. (C) Volcano plot of differentially expressed genes (DEGs), identifying 1258 significant DEGs (532 upregulated, 726 downregulated). (D) KEGG enrichment bubble plot indicates significant suppression of core metabolic pathways, including carbon fixation (p = 2.1e‐6) and oxidative phosphorylation (p = 4.3e‐5). (E) Gene Set Enrichment Analysis (GSEA) confirms the coordinated downregulation of energy metabolism pathways (NES = ‐2.34, p = 0.002). (F) Differential enrichment plot from Gene Set Variation Analysis (GSVA) shows significant downregulation of 12 metabolism‐related functional modules in the treated group (FDR < 0.05). Enrichment analysis was performed using clusterProfiler with Benjamini‐Hochberg correction for multiple testing; FDR < 0.05 was considered statistically significant. (G) Schematic illustration of the antibacterial mechanism of the CGF/PP@MN smart microneedle system against Staphylococcus aureus. At the metabolic network level, KEGG enrichment analysis demonstrated specific inhibition of core metabolic pathways such as carbon fixation and oxidative phosphorylation, validated by their coordinated downregulation in GSEA (Figure 5E). This metabolic suppression directly led to energy depletion. At the level of gene expression programs, operon structure prediction (Figure S9) revealed structural disruption in multiple metabolism‐related operons, and the DEG clustering heatmap (Figure S6) displayed a treatment‐specific gene expression pattern. GSVA (Figure 5F and Figure S8) systematically demonstrated the dysregulation of metabolic functional modules. Integrating these multi‐level findings, Figure 5G schematically illustrates the proposed multi‐pathway antibacterial mechanism of CGF/PP@MN against S. aureus, from initial metabolic interference to eventual bacterial death. This triple mechanism forms a lethal cascade: CGF/PP@MN first disrupts the cell wall structure, forcing bacteria to initiate repair programs; simultaneously, it inhibits the core metabolic network, blocking energy supply; ultimately, it disrupts gene expression programs, depriving bacteria of physiological coordination. The synergistic action across these three levels leads to systemic bacterial collapse, providing a comprehensive molecular explanation for the material's highly efficient antibacterial activity. Notably, experimental results from a rat model with infected skin defects also validated the excellent antibacterial effect of the material group, with wound healing outcomes at 14 days post‐material intervention being significantly superior to the control group (Figures S10 and S11). In summary, the CGF/PP@MN composite material exhibits advanced, broad‐spectrum, and intelligent antibacterial functionality, holding significant application potential in fields requiring precise and efficient microbial control. In Vitro Immunomodulation and Macrophage Polarization The immunomodulatory capacity of the materials was first evaluated by assessing macrophage polarization. As shown in Figure 6A,B, immunofluorescence staining demonstrated distinct morphological changes and marker expression across groups. Quantitative analysis revealed that the CGF/PP@MN group most effectively suppressed the pro‐inflammatory M1 phenotype, evidenced by significantly reduced expression and proportion of iNOS‐positive cells compared to all other groups (Figure 6C,D). Conversely, this group markedly promoted the anti‐inflammatory M2 phenotype, showing the highest expression and percentage of CD206‐positive cells (Figure 6E,F). Consistent with protein‐level observations, qPCR analysis confirmed a potent shift in macrophage functional gene expression. The CGF/PP@MN group significantly upregulated the expression of the M2‐associated gene Arg‐1 (Figure 6G). Simultaneously, it most effectively downregulated the expression of key pro‐inflammatory cytokines, IL‐1β and TNF‐α (Figure 6H,I). The overall efficacy in repolarizing macrophages toward a healing phenotype followed the order: CGF/PP@MN > CGF@MN ≈ PP@MN > MN > Control. Material‐mediated modulation of macrophage polarization. (A, B) Representative immunofluorescence staining images showing the expression of the M1 marker iNOS (red, A) and the M2 marker CD206 (green, B) in macrophages. Nuclei are counterstained with DAPI (blue). Scale bar: 50 µm. Groups from left to right: Control, MN, CGF@MN, PP@MN and CGF/PP@MN. (C) Mean fluorescence intensity of iNOS. (D) Percentage of iNOS‐positive cells. (E) Mean fluorescence intensity of CD206. (F) Percentage of CD206‐positive cells. (G) qRT‐PCR analysis of macrophage functional gene Arg‐1 expression after material intervention: (H, I) ELISA quantification of TNF‐α and IL‐1β. (J) Dot plots show RAW 264.7 cells stained for CD86‐FITC (y‐axis) and CD206‐APC (x‐axis). Compared with the control and MN groups, CGF@MN, PP@MN, and CGF/PP@MN promoted a rightward shift toward higher CD206 expression with attenuated CD86 signals. The CGF/PP@MN group exhibited the most pronounced accumulation in the CD206‐high region, indicating superior M2 polarization. *Data for all quantitative panels (C‐I) are presented as mean ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001. To quantitatively assess the effect of materials on M1/M2 macrophage polarization, the expression of surface markers CD86 (M1 phenotype) and CD206 (M2 phenotype) was analyzed by flow cytometry. After co‐treatment with LPS (200 ng/mL) and different materials for 36 h, RAW 264.7 cells were collected, stained with fluorophore‐conjugated antibodies against CD86 and CD206, and analyzed using a flow cytometer. Data analysis revealed a distinct shift in macrophage populations upon material intervention. Compared to the Control and MN groups, cells treated with CGF@MN, PP@MN, and notably CGF/PP@MN showed a marked increase in the CD206‐positive (M2) population coupled with a decrease in CD86‐positive (M1) signals (Figure 6J). Flow cytometry quantified a significant shift in the macrophage population, with the CGF/PP@MN group showing the highest proportion of CD206‐high cells (Figure 6J), quantitatively demonstrating its superior efficacy in driving polarization toward the anti‐inflammatory M2 phenotype. The functional consequence of this immunomodulation was assessed using a conditioned medium model. Macrophages treated with CGF/PP@MN secreted factors that created a pro‐regenerative milieu, which most potently suppressed pro‐inflammatory genes (iNOS, IL‐1β, TNF‐α) in fresh macrophages (Figure 7E‐G) and, when applied to BMSCs, most effectively enhanced the expression of early osteogenic genes (Runx2, ALP, OCN) in BMSCs (Figure 7H,I). Critically, all materials, including CGF/PP@MN, exhibited excellent cytocompatibility, supporting high cell viability for both RAW264.7 cells and BMSCs (Figure 7A‐D). Cytocompatibility and osteo‐immunomodulatory effects of the materials.(A) Representative live/dead fluorescence images of RAW264.7 macrophages (bottom row) and bone marrow mesenchymal stem cells (BMSCs, top row) after 3 days of culture with different materials. Live and dead cells are stained green and red, respectively. Scale bar = 200 µm. Groups: control, MN, CGF@MN, PP@MN, CGF/PP@MN. (B) Quantitative analysis of BMSC viability assessed by CCK‐8 assay, expressed as absorbance (OD) at 450 nm. (C, D) Representative quantification of live/dead cell staining for (C) BMSCs and (D) RAW264.7 cells. (E‐G) qRT‐PCR analysis of pro‐inflammatory gene expression (IL‐1β, TNF‐α, iNOS) in RAW264.7 macrophages cultured directly with the indicated materials. (H, I) qRT‐PCR analysis of early osteogenic gene expression (Runx2, ALP, OCN) in BMSCs cultured with conditioned medium derived from macrophages that had been exposed to the corresponding material formulations. *Data for all quantitative panels (B‐I) are presented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. The enhanced anti‐inflammatory efficacy of the CGF/PP@MN group in vitro stems from the synergistic interactions within its spatiotemporal release framework. The surface‐anchored PP peptide delivers immediate interfacial signals to resident macrophages, thereby initiating early‐stage immunomodulation. Concurrently, the sustained release of bioactive factors from the encapsulated CGF core ensures the continuity of pro‐regenerative signaling. This temporally coordinated mechanism, characterized by rapid initiation mediated by PP and prolonged maintenance facilitated by CGF, promotes a more robust and durable shift toward the M2 phenotype than that achieved by either component in isolation. Consequently, the resulting anti‐inflammatory secretome effectively primes bone marrow mesenchymal stem cells for osteogenic differentiation, demonstrating a potent osteo‐immunomodulatory capacity. In Vitro Osteogenic The direct osteogenic potential on BMSCs was rigorously evaluated. After 14 days of osteogenic induction, the CGF/PP@MN group demonstrated the most pronounced matrix mineralization, as indicated by the most intense and extensive Alizarin Red S (ARS) staining (Figure 8A,C). Concurrently, this group exhibited the strongest Alkaline Phosphatase (ALP) activity, a marker of early osteogenic differentiation (Figure 8A,D). Western blot analysis corroborated the staining results at the molecular level. The expression of key osteogenic proteins, including the master transcription factor Runx‐2, the bone matrix protein Osteopontin, and the major collagen COL1‐a1, was most significantly upregulated in the CGF/PP@MN group compared to all other treatments (Figure 8B). Densitometric quantification confirmed these proteins were markedly increased in the CGF/PP@MN group (Figure 8E‐G). Enhancement of osteogenic differentiation in BMSCs by material intervention. (A) Representative images of histological staining for osteogenic markers after 14 days of induction. Top row: Alizarin Red S (ARS) staining, indicating calcium nodule formation. Bottom two rows: Alkaline Phosphatase (ALP) staining, indicating early osteogenic activity. Groups: control, MN, CGF@MN, PP@MN, CGF/PP@MN. (B) Representative Western blot analysis showing protein expression levels of key osteogenic markers: Runt‐related transcription factor 2 (Runx‐2), Collagen type I alpha 1 (COL1‐a1), and Osteopontin. β‐actin serves as the loading control. (C, D) Quantitative analysis of (C) mineralized area by ARS staining and (D) ALP activity. (E‐G) Densitometric quantification of protein expression levels from (B) for (E) Runx‐2, (F) COL1‐a1, and (G) Osteopontin, normalized to β‐actin. *Data for all quantitative panels (C‐G) are presented as mean ± SD (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001. The exceptional osteogenic efficacy of CGF/PP@MN originates from a dual‐pathway mechanism enabled by its vertical structural framework. First, the system indirectly promotes osteogenesis by shaping an optimal osteoimmune microenvironment through macrophage reprogramming. Second, it provides direct and sustained osteogenic stimulation to bone marrow mesenchymal stem cells. The CGF core functions as a local, long‐term reservoir of growth factors, continuously driving the osteogenic differentiation of these cells. Concurrently, the PP component contributes by mitigating the inflammatory phase that typically impedes bone healing. This spatiotemporally coordinated strategy is characterized by the PP component rapidly modulating the initial immune response, while the CGF core delivers sustained anabolic signals. This ensures that the regenerative process progresses sequentially from inflammation resolution to active bone formation. The synergy between these components within a single delivery system comprehensively explains the system's superior performance in enhancing alkaline phosphatase activity, promoting matrix mineralization, and augmenting osteogenic protein synthesis. In Vivo Osteogenic Micro‐CT scanning at 4 and 8 weeks post‐implantation revealed progressive bone regeneration across all groups (Figure 9A,B), with significant differences in quantitative parameters. The CGF/PP@MN group demonstrated the highest osteogenic efficacy, achieving a bone volume fraction (BV/TV) of 63.2±3.2% at 8 weeks, significantly exceeding the CGF@MN group (50.2±2.9%) and PP@MN group (33.6±2.6%) (P<0.01). Trabecular number (Tb.N) reached 3.1±0.3mm−1 in CGF/PP@MN, compared to 2.5±0.2mm−1 in CGF@MN and 2.1±0.2mm−1 in PP@MN (Figure 9C). Bone mineral density (BMD) followed the same trend, with CGF/PP@MN attaining 0.64±0.05g/cm3 at 8 weeks, indicating superior mineralization quality (Figure 9D). In contrast, the control and MN groups exhibited limited regeneration, with BV/TV below 25% and disorganized trabecular structure. Evaluation of bone regeneration in a diabetic rat calvarial defect model treated with different microneedle (MN) systems. (A)Schematic illustration of the experimental timeline. (B)Representative 3D reconstructed micro‐CT images of calvarial defects at 4 and 8 weeks post‐implantation, showing new bone formation across groups: Control, MN, PP@MN, CGF@MN, and CGF/PP@MN. (C‐D)Quantitative analysis of bone regeneration parameters: (C) bone volume fraction (BV/TV, %) and (D) bone mineral density (BMD, g/cm3). (E)Histological evaluation via H&E and Masson's trichrome staining at 4 and 8 weeks. H&E staining reveals new bone architecture and cellularity (red arrows: osteocytes; black arrows: residual fibrovascular tissue). Masson's staining highlights collagen deposition (blue) and mature bone matrix (red). Scale bars: 100 µm. Data are presented as mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001, *** p < 0.0001. H&E staining of major organs (heart, liver, spleen, lung, kidney) revealed normal tissue architecture without pathological alterations in all groups. Semi‐quantitative histopathological scoring showed negligible inflammatory cell infiltration (scores 0–1) and absence of tissue necrosis or degeneration. No significant differences were observed between material‐treated groups and controls, confirming excellent histocompatibility and biosafety profiles (Figure S14). H&E and Masson's trichrome staining at 4 weeks indicated robust new bone formation in the CGF/PP@MN group, characterized by abundant osteocytes and well‐aligned collagen fibers. By 8 weeks, CGF/PP@MN achieved near‐complete defect closure with mature lamellar bone, while CGF@MN showed moderate bone deposition with residual fibrovascular tissue, and PP@MN displayed sporadic bone islands. Quantitative analysis of Masson's staining revealed collagen deposition areas of 68.4±4.8% in CGF/PP@MN, significantly higher than 52.7±3.9% in CGF@MN and 45.3±3.5% in PP@MN (P<0.05between groups) (Figure 9E). Histochemical staining and immunofluorescence (IF) detection confirmed the superior performance of the CGF/PP@MN composite material in diabetic bone defect repair at the protein expression level. Temporal analysis of key osteogenic markers revealed that this material group exhibited significant advantages in promoting bone matrix deposition, osteoblast differentiation, and bone tissue maturation. The immunohistochemical (IHC) results for Col‐1 and Runx‐2 presented in Figure 10A demonstrate distinct temporal patterns. At 4 weeks post‐implantation, extensive Col‐1 positive expression was already observed in the defect area of the CGF/PP@MN group, indicating active early extracellular matrix synthesis. Concurrently, the number of Runx‐2 positive cells was markedly higher compared to control groups, suggesting an accelerated osteoblast differentiation process. By week 8, this advantage became more pronounced: Col‐1 positive areas displayed a dense, mesh‐like structure, and the density of Runx‐2 positive cells further increased, demonstrating sustained and active osteogenesis. This temporal progression aligns well with the established biological sequence of normal bone healing. CGF/PP@MN microneedle patch significantly enhances osteogenic and angiogenic capacity in a diabetic bone defect model. (A) Representative immunohistochemical staining images for osteogenic markers Type I Collagen (Col1‐a1) and Runt‐related transcription factor 2 (Runx‐2) at 4 and 8 weeks post‐implantation. Stronger positive staining (brown) in the CGF/PP@MN group indicates enhanced extracellular matrix deposition and osteogenic differentiation. (B‐E) Quantitative analysis of the positive area ratio (positive area/tissue area) for Col1‐a1 (B, C) and Runx‐2 (D, E) at 4 weeks and 8 weeks. (F) Immunofluorescence staining for late osteogenic markers Osteocalcin (OCN, red), Osteopontin (OPN, red), and CD31(red) at 8 weeks. Nuclei are counterstained with DAPI (blue). The intense fluorescence signals in the CGF/PP@MN group suggest advanced bone maturation and mineralization. Scale bars: 100 µm. Data are presented as mean ± SD; * p < 0.05, ** p < 0.01, *** p < 0.001. Quantitative analyses (Figure 10B–E) provided robust statistical support for these observations. Notably, the Col‐1 positive area ratio in the CGF/PP@MN group reached 27.3% at 8 weeks, significantly higher than that in all other groups (P < 0.01), indicating the material's ability to continuously promote collagenous matrix deposition. The quantitative results for Runx‐2 were equally compelling. Its positive area ratio significantly increased to 43.3% at the experimental endpoint from 32.42% at 4 weeks (P < 0.05), confirming the maintenance of robust osteogenic differentiation activity over an extended period. Immunofluorescence (IF) results in Figure 10F revealed strong co‐expression of two critical non‐collagenous bone matrix proteins, osteocalcin (OCN) and osteopontin (OPN), in the CGF/PP@MN group during the later stages of repair. Concurrently, intense CD31 (platelet endothelial cell adhesion molecule) staining in this group indicated substantial neovascularization within the defect area. The robust OCN signal, a marker of late‐stage bone formation, signifies that the newly formed bone tissue had progressed into the mineralization and maturation phase. The high expression of OPN suggests active bone remodeling processes. Furthermore, the pronounced CD31 expression confirms adequate vascularization accompanying bone regeneration, which is crucial for ensuring nutrient supply, metabolic waste removal, and the long‐term viability of the neobone tissue. The synergistic high expression of OCN, OPN, and CD31 provides molecular and histological evidence that the newly formed bone not only approximates normal bone in terms of mineralization maturity and remodeling activity but has also established a functional vascular network, achieving high‐quality and viable bone regeneration. We attribute this exceptional osteogenic efficacy to the dual advantages inherent in the material's design. Firstly, the sustained and controlled release of CGF, facilitated by the GelMA hydrogel, ensures spatiotemporally rational delivery of growth factors (including pro‐angiogenic factors such as VEGF) — a rapid initial release addresses the demands of the inflammatory phase, while subsequent sustained release supports angiogenesis and osteogenesis during the repair phase. Second, the tailored bioresponsive PP peptide precisely modulates the local immune microenvironment. Specifically, by promoting macrophage polarization toward the M2 phenotype, upregulating anti‐inflammatory factors (e.g., IL‐10), and suppressing pro‐inflammatory factors (e.g., TNF‐α), it effectively ameliorates the compromised bone‐healing microenvironment characteristic of the diabetic state. M2 macrophages themselves can secrete pro‐angiogenic factors, which act synergistically with the sustained release of CGF, collectively explaining the superior osteogenic and angiogenic outcomes observed in the CGF/PP@MN group. This dual‐strategy system, combining “sustained release of biological factors” with “immunomodulation of the local microenvironment,” creates a favorable synergistic effect across molecular, cellular, and tissue levels. This approach not only accelerates the bone defect repair process but, more importantly, ensures the quality of the regenerated bone, offering a promising new therapeutic strategy for the challenging clinical problem of diabetic bone defects. The superior bone regeneration observed in the CGF/PP@MN group can be attributed to the synergistic interplay between its components. Concentrated Growth Factor (CGF) provides a rich reservoir of osteoinductive factors (e.g., VEGF, TGF‐β, and PDGF), which directly stimulate angiogenesis and osteoblast differentiation. The peptide‐modified microneedle (PP@MN) platform contributes through its dual‐bioresponsive properties: (1) gelatinase‐responsive release of antibacterial peptides mitigates infection risk, and (2) glutathione‐responsive immunomodulatory peptides promote M2 macrophage polarization, thereby resolving chronic inflammation. This combinatorial strategy ensures spatiotemporally controlled factor delivery, aligning with the phased requirements of bone healing—initial anti‐inflammatory and antibacterial action followed by sustained osteogenic stimulation. The integrated system thus addresses key limitations of diabetic bone defects, including impaired cellular differentiation and dysregulated immune responses, resulting in enhanced microarchitectural maturity and functional restoration. All quantitative data represent mean ± SD from three independent experiments. Statistical significance was determined by one‐way ANOVA with Tukey's post‐hoc test (* p< 0.05, ** p < 0.01, *** p < 0.001). In Vivo Antibacterial Efficacy Integrated analysis of three in vivo experimental assessments demonstrates that CGF/PP@MNs co‐loaded microneedles exhibit remarkable multi‐dimensional antibacterial efficacy in a rat cranial infection model. First, quantitative crystal violet staining analysis (Figure S15) revealed the outstanding anti‐biofilm capability of this formulation, achieving a biofilm biomass inhibition rate as high as 87.49%, significantly superior to single‐agent loaded groups (CGF@MNs: 45.74%; PP@MNs: 57.09%). This indicates a significant synergistic effect between CGF and PP within the microneedle delivery system, effectively disrupting the protective extracellular matrix barrier of bacteria. Building upon the disruption of the biofilm barrier, colony counting results further confirmed its potent in vivo bactericidal activity (Figure S16). The colony‐forming unit (CFU) value in the CGF/PP@MNs treatment group was significantly lower than that of the control group, quantitatively reflecting the formulation's effective clearance of viable bacteria in bone tissue. Combined with the anti‐biofilm effect, these findings suggest that CGF/PP@MNs controls infection through a dual‐mechanism approach of “disrupting biofilm structure – eliminating planktonic bacteria.” Gram staining at the histological level provided visual morphological evidence for the aforementioned functions (Figure S17). After 7 days of treatment with CGF/PP@MNs, bone tissue sections showed only minimal purple‐blue bacterial residues, whereas the control group exhibited dense bacterial colonization. Concurrently, inflammatory cell infiltration at the infection site in the treatment group was markedly reduced, and the integrity of the bone tissue structure was better preserved. This suggests that while exerting potent antibacterial effects, CGF/PP@MNs also create conditions for tissue repair by modulating the local immune microenvironment. Discussion Sequential and Synergistic Therapy: A Programmable Platform for Diabetic Bone Regeneration Conventional therapeutic approaches for tissue regeneration in complex pathologies such as diabetic bone defects are often challenged by their inability to coherently intervene in the dynamic, multi‐stage healing cascade. The core pathophysiology of impaired diabetic bone healing lies in a vicious cycle of persistent inflammation, heightened infection risk, and suppressed osteogenesis [6]. Recent advanced strategies, including functionalized scaffolds [6] or specific signaling molecules that reprogram macrophage polarization toward a pro‐regenerative M2 phenotype via pathways like PI3K/AKT, PPARγ [68], TLR4/NF‐κB inhibition [69], or ERK activation, represent significant progress in “immunometabolic reprogramming” [70, 71]. Further innovative approaches, such as the engineered wasp venom peptide Mast‐MO, exemplify a “dual‐function” strategy combining direct antibacterial activity with host‐directed immunomodulation (e.g., cytokine suppression and indirect M2 polarization) [57]. While promising, these strategies primarily focus on delivering one or two static bioactive cues at a single time point, failing to fully recapitulate the precise temporal logic inherent to physiological healing, where immune regulation, infection control, and tissue regeneration are sequentially and seamlessly coupled. Therefore, developing a strategy capable of actively sensing pathological changes and executing multiple therapeutic functions according to a pre‐programmed sequence is key to overcoming current limitations. While promising, these strategies primarily focus on delivering one or two static bioactive cues at a single time point, failing to fully recapitulate the precise temporal logic inherent to physiological healing, where immune regulation, infection control, and tissue regeneration are sequentially and seamlessly coupled. Therefore, developing a strategy capable of actively sensing pathological changes and executing multiple therapeutic functions according to a pre‐programmed sequence is key to overcoming current limitations. Compared to the state‐of‐the‐art in the field, the CGF/PP@MN microneedle system developed herein demonstrates superiority not merely through functional additivity but through sophisticated response logic and deep functional integration. As noted, leading studies have achieved “antimicrobial‐immunomodulatory” duality (e.g., Mast‐MO) [57] or “immune‐osteogenic” coupling via specific pathways [68]. Our work constructs a more advanced triple‐sequenced response system: (1) immediate physical disruption and rapid release of surface‐conjugated PP peptides for early immunomodulation; (2) infection‐microenvironment‐triggered, on‐demand release of antimicrobial peptides for precise bactericidal activity; and (3) sustained release of CGF core components for long‐term immune stabilization and continuous osteoinductive signaling. This design transforms three critical processes—“immune remodeling”, “on‐demand antimicrobial action”, and “sustained osteogenesis” from a simple functional combination into a synergistic therapeutic program with intrinsic causal and temporal relationships. The observed efficacy (CGF/PP@MN > CGF@MN ≈ PP@MN > MN) results not from linear addition but from temporal synergy, validating the advantage of complex response logic in addressing complex pathologies. An ideal bone repair scaffold must not only provide temporary mechanical support and bioactive signals, but its degradation rate should also be coordinated with the natural progression of tissue regeneration. The GelMA hydrogel employed in this study undergoes degradation primarily through enzymatic hydrolysis and slow hydration. Although a complete long‐term in vitro degradation profile was not presented in the main text, based on extensive literature on GelMA materials and their performance in our in vivo model, we can infer that its degradation timeline aligns with the critical 8‐week window for bone regeneration. The relatively slow yet continuous degradation offers dual advantages: during the early healing phase, the microneedles maintain structural integrity, providing a stable three‐dimensional framework for cell recruitment and tissue ingrowth while ensuring effective local retention of early‐stage therapeutic factors; during the mid‐to‐late phase, gradual matrix degradation facilitates sustained release of CGF complexes encapsulated in the core, providing prolonged bioactive signals for ongoing vascularization and osteogenesis, while avoiding long‐term material retention that might provoke foreign body responses. This design philosophy aligns with cutting‐edge research in bone tissue engineering. For instance, recent studies utilizing silk fibroin methacryloyl (SilMA) hydrogel microspheres for bone organoid construction demonstrated that slow degradation kinetics—approximately 20% degradation over 30 days—proved essential for maintaining cell viability, osteogenic differentiation, and function during long‐term in vitro culture [72]. Similarly, in intelligent repair strategies for diabetic bone defects, maintaining scaffold stability over several weeks to ensure sustained delivery of therapeutic signals is considered critical for achieving high‐quality regeneration [73]. Compared to rapidly degrading systems, the material employed in our system, with degradation kinetics covering the critical healing phase, is better suited to meet the requirements for long‐term support and signal delivery in the chronic, complex pathological environment of diabetic bone defects. Nevertheless, degradation should not be excessively slow; the ideal scenario involves a rate slightly slower than or synchronized with new bone deposition, allowing nascent tissue to gradually replace the scaffold material. Future work could further optimize the degradation profile by precisely modulating GelMA crosslinking density or introducing degradation linkages responsive to specific pathological cues within the lesion microenvironment, thereby achieving more precise alignment with individualized repair processes. In summary, the core of the “vertical integration of pathological dysregulation” strategy proposed in this work transcends conventional parallel functional combinations, specifically the “horizontal” integration approach exemplified by simply co‐loading anti‐inflammatory, antimicrobial, and osteogenic factors. Instead, it constructs a therapeutic sequence that synergizes along both the temporal axis and the depth of pathophysiology. As illustrated schematically in Figure 1, the pathological progression of diabetic bone defects unfolds as a hierarchical cascade: chronic immune‐inflammatory dysregulation constitutes the foundational layer, upon which an elevated risk of infection is superimposed, ultimately converging to impair osteogenesis. Addressing this stratified pathological architecture, the three functional modules of our system achieve precise vertical alignment and sequential activation. The GSH‐responsive pro‐AIP is designed to fundamentally reverse immune dysregulation at its source by promoting M2 macrophage polarization during the early phase, thereby establishing the prerequisite conditions for subsequent repair. The MMPs‐responsive pro‐AMP intervenes during the early‐to‐mid phase to eliminate infectious complications, including biofilms that readily form within the inflammatory milieu. Concurrently, the sustained release of CGF from the core reservoir operates throughout the mid‐to‐late phases within the now‐optimized microenvironment, persistently driving angiogenesis and osteogenesis toward the ultimate regenerative goal. Therefore, the “vertical integration” embodied by our system represents a logic of in‐depth intervention. It is not merely a superposition of multiple functions, but rather a programmed and synergistic dismantling of interconnected pathological barriers orchestrated according to the intrinsic sequence of disease progression. This fundamentally distinguishes our approach from the predominant paradigm in existing research, which largely focuses on providing multiple, albeit concurrent, functions at a single temporal or pathological level, representing a “horizontal” combination of capabilities. We believe that this “pathology‐progression‐oriented” vertical integration design philosophy provides a new conceptual framework for developing intelligent therapeutic strategies to address other complex chronic tissue defects. Microbiome and Responsive Antimicrobial Strategies Biofilm formation at diabetic wound sites limits drug penetration and sustains chronic infection, conferring high levels of resistance to conventional antibiotics [74]. Antimicrobial peptides (AMPs) have recently gained attention as promising alternatives, capable of disrupting microbial membranes and bypassing traditional resistance mechanisms [75]. AMPs show potent activity against multidrug‐resistant pathogens such as methicillin‐resistant Staphylococcus aureus (MRSA) by compromising membrane integrity and inhibiting biofilm formation [76, 77]. Their broad‐spectrum action and biofilm‐penetrating ability make them particularly suitable for managing complex diabetic wound infections. The synthetic tetrapeptide BRBR‐NH2 exhibits rapid and potent bactericidal activity against S. aureus, with a low MIC of 6.25 µm [56]. It acts via the SMART mechanism, targeting bacterial membranes through electrostatic and hydrophobic interactions with anionic phospholipids. Cationic arginine residues facilitate membrane binding, while hydrophobic biphenyl groups enable membrane insertion, leading to disruption and cell lysis. BRBR‐NH2 selectively targets anionic membranes, remains unstructured in solution, and is effective against drug‐resistant strains, underscoring its potential as a topical antibacterial agent. These responsive antimicrobial and anti‐biofilm strategies not only eradicate pathogens but may also contribute to restoring a healthy local microbiome. While the transcriptomic data support a model of triple synergistic action, it is important to note that this mechanism is inferred from coordinated gene expression changes rather than direct functional validation of each component. The upregulation of genes (Table S1) suggests potential cooperation, but conclusive evidence of their mechanistic interaction would require further targeted experiments, such as genetic perturbation or protein‐level activity assays. Thus, the proposed model should be considered a working hypothesis that provides a focused narrative for future investigation. Consideration on Macrophage Phenotype Persistence and System Advantages This study has demonstrated in vitro that the CGF‐loaded MN patch effectively promotes macrophage polarization toward the pro‐regenerative M2 phenotype within 36 h. However, a prudent assessment of the persistence of this beneficial phenotype in the chronically inflammatory milieu of diabetic bone defects is critical for evaluating its clinical translation potential. Macrophages exhibit remarkable phenotypic plasticity; their polarization state is not fixed but is dynamically regulated by signals in the local microenvironment [78, 79]. Under chronic inflammatory stimuli, polarized M2 macrophages risk repolarizing to the pro‐inflammatory M1 phenotype. Furthermore, the turnover and replenishment of macrophages at the injury site is an ongoing process [79], necessitating long‐term, continuous immunomodulatory signals to persistently “educate” newly infiltrating monocytes/macrophages to maintain a stable pro‐repair microenvironment. The dual‐stimuli‐responsive MN delivery system developed here provides an innovative solution to this challenge. The system's potential for sustained efficacy stems from two synergistic release mechanisms: First, the stimulus‐responsive sustained release of the active ingredient, particularly the anti‐inflammatory peptide pro‐AIP. As shown in Figure 3M,N, pro‐AIP exhibits a non‐burst, sustained, and incremental release profile under high GSH conditions mimicking the oxidative‐stress‐rich microenvironment of diabetic bone defects. This indicates that the system can responsively and continuously release AIP for as long as the inflammatory/oxidative stress state persists at the lesion site, mimicking the regulatory role of sustained physiological signals (e.g., neurosensory secretion like CGRP [80]) to provide long‐term M2 polarization and maintenance signals for macrophages. Second, the biodegradation process of the MN matrix material itself. The gradual hydrolytic degradation of the microneedles in tissue fluid provides an alternative, slow, and sustained release pathway for the encapsulated CGF composite. Consequently, our system's design transcends a single bolus administration. Through the combined strategy of “intelligent triggered release” and “matrix‐mediated sustained release,” it holds promise for maintaining a localized drug microenvironment of sufficient concentration to promote M2 polarization over the critical days‐to‐weeks window of bone defect healing. This sustained stimulation is crucial for counteracting chronic diabetic inflammation, preventing unfavorable reversal of macrophage phenotype, and continuously guiding newly recruited immune cells toward a reparative phenotype. Future studies involving longer‐term chronic inflammation models will directly monitor the dynamic changes in macrophage phenotypes to quantify the duration and efficacy of M2 phenotype maintenance by this system. Osteogenic Role of CGF In the complex microenvironment of diabetic bone defects, effective osteogenesis and angiogenesis are central to the regeneration process. Concentrated Growth Factor (CGF), an autologous bioactive concentrate derived from peripheral blood, is enriched with numerous osteogenic growth factors and cytokines known to significantly enhance bone regeneration [81, 82, 83]. The osteogenic potential of CGF stems not only from the direct release of these factors but also from activation of critical signalling pathways. Notably, TGF‐β1 has been identified as a pivotal mediator that promotes osteoblastic differentiation and matrix mineralization via paracrine mechanisms [82]. However, a major barrier to the clinical translation of CGF—shared with many growth factor‐based therapies—is its rapid diffusion and short half‐life, leading to suboptimal spatiotemporal presentation and reduced bioactivity [84, 85]. Overcoming these limitations requires advanced delivery systems that preserve growth factor stability and enable precise control over release kinetics.GelMA, a photopolymerizable derivative of gelatin modified with methacryloyl groups, undergoes rapid cross‐linking upon exposure to UV or visible light in the presence of a photoinitiator. This material amalgamates the beneficial properties of both natural and synthetic biomaterials, providing a three‐dimensional microenvironment that facilitates cell proliferation and differentiation, while also exhibiting high biocompatibility and customizable cellular interactions. These characteristics position GelMA as a viable alternative to traditional artificial basement membranes or collagen‐based hydrogels [86, 87]. Furthermore, GelMA exhibits thermoresponsive gelation, controllable biodegradability, adjustable mechanical properties, and inherent bioactivity that enhances osteogenesis and vascularization. As a result, it has been widely utilized in bone tissue engineering and regenerative repair applications [88, 89]. Building on established research, hydrogels have been extensively demonstrated as effective carriers for therapeutic molecules, facilitating sustained and spatiotemporally programmable release of encapsulated drugs or growth factors over extended durations‐often exceeding one month‐due to diffusion‐controlled mechanisms and adjustable matrix degradation kinetics [90, 91, 92, 93]. Consequently, the encapsulation of concentrated growth factors (CGF) within a GelMA hydrogel matrix effectively mitigates the typical rapid initial release, enabling a precisely controlled, phase‐dependent elution of bioactive factors. This temporal release profile is strategically aligned with the sequential stages of bone regeneration, including inflammatory resolution, osteogenic repair, and remodeling, thereby ensuring sustained bioactivity throughout the bone regeneration process. Aptamer‐based systems represent a promising approach, leveraging the selective affinity and conformational flexibility of nucleic acid aptamers for orchestrated, spatiotemporally controlled co‐delivery of multiple factors [94]. The dynamic reciprocity between cells and the extracellular matrix (ECM) during bone healing further underscores the need for biomimetic carrier systems that adapt to the evolving regenerative microenvironment [94]. Therefore, integrating CGF into intelligent, aptamer‐functionalized delivery platforms offers a viable strategy to enhance factor retention, prevent premature inactivation, and synchronize growth factor release with the complex chronology of bone repair. The CGF‐loaded microneedles described herein employ this strategy to exert their osteogenic effects. This system is conceptualized as a “bioinspired coupler,” with its core biomimetic logic residing in the precise mirroring of the physiological phase sequence of normal bone healing by the release order of its therapeutic modules. Natural bone repair is a highly coordinated, multi‐stage, continuous biological process: it begins with the inflammatory phase, characterized by pathogen clearance, immune cell recruitment, and initiation of anti‐inflammatory responses; subsequently, it transitions into the repair phase, dominated by angiogenesis and bone matrix deposition; and finally progresses to the remodeling phase, involving matrix mineralization and structural optimization. Our MN system actively mimics and couples this sequence through its compartmentalized design and stimulus‐responsive logic. The surface‐loaded responsive peptides constitute the “first responder echelon”: in the early post‐implantation stage, responding to the inflammatory and infectious microenvironment characterized by elevated GSH and MMPs, the rapid release of pro‐AIP and pro‐AMP executes early immunomodulation and antibacterial functions, respectively. This directly corresponds to and reinforces the objectives of the “inflammatory phase” of physiological healing, namely controlling infection and reversing the pro‐inflammatory state to create a clean, anti‐inflammatory microenvironment conducive to repair. The core‐encapsulated CGF constitutes the “sustained effector echelon”: as inflammation is brought under control, the gradual degradation of the microneedle matrix and sustained release of CGF provide prolonged angiogenic and osteogenic signals. This seamlessly engages and drives the key events of the repair and early remodeling phases, including vascularization, osteoblast differentiation, and osteoid deposition and mineralization. Therefore, the release from the system is neither random nor parallel; it follows a predetermined timeline of “immunomodulation/antibacterial action first, sustained osteogenesis/angiogenesis second.” This actively guides the disordered healing process within the pathological environment back onto an orderly repair trajectory resembling the physiological state. This biomimetic “coupling” to the natural healing sequence constitutes the underlying reason for the system's ability to break the vicious cycle of chronic inflammation in diabetic bone defects and achieve high‐quality regeneration. Sequential Therapeutic Platform Unifies Immunomodulation and High‐Quality Bone Regeneration The superior regenerative efficacy of the CGF/PP@MN system stems from its rational material design, which intelligently intervenes in and corrects the pathodynamic processes underlying diabetic bone healing. By integrating mechanism‐driven immunomodulation with temporally programmed bioactive factor delivery, this platform transcends conventional biomaterial strategies to achieve a unified therapeutic outcome, culminating in the formation of structurally and functionally mature bone. The compartmentalized architecture of the microneedle patch provides the foundation for spatiotemporal control. The surface‐conjugated dual bioresponsive peptide platform acts as a frontline microenvironmental sensor, with its components selectively activated by specific pathological cues of the diabetic defect—glutathione in oxidative stress and MMP‐2/9 in the proteolytic milieu—ensuring that immunomodulatory and antimicrobial mechanisms are deployed precisely when and where they are most needed. Concurrently, the GelMA hydrogel core encapsulates CGF, serving as a reservoir for the sustained release of a combinatorial repertoire of osteogenic and angiogenic morphogens. This dual‐release paradigm, combining rapid surface responsiveness with prolonged core release, embodies the material realization of spatiotemporal therapeutic logic. The therapeutic efficacy unfolds through a meticulously orchestrated sequence of mechanisms, each validated by experimental evidence. In the early post‐implantation phase, the surface‐responsive AIP is released to actively reprogram the hostile immune environment. By promoting macrophage polarization toward the M2 phenotype, it converts the chronic inflammatory state into a pro‐regenerative milieu, thereby establishing an “ordered immune microenvironment.” This step is a prerequisite for interrupting the vicious cycle of inflammation‐impaired healing characteristic of diabetes. Within this permissive microenvironment, sustained release of CGF from the degrading GelMA core provides unwavering support for the cellular processes of bone formation. Persistently elevated Runx‐2 expression indicates maintained osteogenic differentiation activity, while the widespread and dense deposition of Col‐1 reflects high‐fidelity extracellular matrix synthesis. Ultimately, this coordinated action directly drives superior bone quality. Sustained growth factor provision supports late‐stage osteogenesis, evidenced by strong co‐expression of the mineralization‐associated proteins OCN and OPN, coupled with a significant increase in bone mineral density. Histologically, this translates into the formation of mature lamellar bone with regularly aligned collagen fibers, representing a qualitative shift from a high‐volume trabecular network to a densely mineralized, ordered structure that transcends mere volumetric accumulation. In this study, the results from the PP@MN control group provide critical evidence supporting the rationale behind the core‐shell synergistic design. This group contained only the responsive peptide platform (pro‐AMP/pro‐AIP), enabling immunomodulatory and antimicrobial functions. Experimental results demonstrated that while the PP@MN group exhibited certain efficacy in improving the local inflammatory microenvironment by promoting M2 macrophage polarization, its ultimate bone regeneration outcomes, including BV/TV, BMD, and lamellar bone formation, were significantly inferior to those achieved by the complete CGF/PP@MN system. This comparison clearly indicates that in diabetic bone defects, rectifying the immune microenvironment alone, while necessary, is not sufficient. Creating a pro‐regenerative immune environment clears obstacles for subsequent stem cell recruitment, osteogenic differentiation, and matrix mineralization. However, without sustained and adequate osteogenic and angiogenic signals provided by the CGF core reservoir to drive and sustain this regenerative program, the bone healing process stalls at an early stage, failing to achieve complete reconstruction of high‐quality bone tissue. Therefore, the performance disparity between the PP@MN and CGF/PP@MN groups directly validates the core logic of our design: the immediate, intelligent response of the shell (PP) paves the way for bone regeneration, while the sustained release from the core (CGF) provides the energy and guidance for the regenerative process. The indispensable spatiotemporal coordination of these two components together constitutes a complete therapeutic solution for achieving functional bone regeneration under diabetic conditions. Comparative Analysis with State‐of‐the‐Art Smart Diabetic Bone Regeneration Systems and Future Perspectives The CGF/PP@MN implantable microneedle system developed in this study addresses the complex challenges of diabetic bone defects, including immune dysregulation, infection risk, and impaired osteogenesis, aligning with the objectives of numerous recent advanced smart biomaterials [36, 95, 96, 97, 98]. Nevertheless, through its unique integrated design, our system establishes distinctive characteristics in device format, therapeutic autonomy, and functional synergy. Compared to the multi‐signal responsive implantable hydrogel reported by Li et al. [95], our system encapsulates intelligent responsiveness to GSH and MMPs within a microneedle array, where the micron‐scale architecture and stratified loading capacity may enable more precise spatiotemporal distribution and efficient utilization of therapeutic agents at the defect site. In contrast to the piezoelectric‐immunomodulatory hydrogel requiring external ultrasound stimulation described by Dong et al. [97], our system is entirely driven by endogenous biochemical signals, achieving self‐triggered therapeutic intervention without external manipulation. Furthermore, relative to implantable materials such as the dual‐responsive glass scaffold developed by Tian et al. [36] and the sequentially releasing biomimetic periosteum reported by Zhuang et al. [98], the microneedle array provides substantially greater specific surface area and tissue‐interlocking potential, which may enhance early stabilization and signal transduction. Compared to photothermal systems utilizing near‐infrared light for therapeutic activation as demonstrated by Wu et al. [96], our system explores a purely endogenous biochemical signal‐triggered pathway, offering a simpler and safer autonomous response paradigm for intelligent implantable device design. In summary, the core innovation of this work lies in integrating a fully endogenous stimulus‐responsive cascade therapeutic program specifically tailored for diabetic bone defects within a miniaturized, integrated implantable microneedle platform. This program encompasses immunomodulation, antimicrobial activity, and osteogenesis in a coordinated sequence. The resulting platform provides a novel paradigm for developing next‐generation intelligent bone repair devices capable of autonomously sensing the pathological microenvironment and executing precisely sequential therapeutic programs. Future research directions may include optimizing the mechanical properties of the microneedles for load‐bearing bone applications and investigating long‐term efficacy and biosafety in larger, more complex bone defect models. Limitations and Future Perspectives While the in vitro co‐culture experiments in this study provide direct evidence supporting the crucial mechanistic link that “M2‐polarized macrophages enhance osteogenesis,” it must be acknowledged that this causal “immunomodulation‐osteogenesis enhancement” axis requires more direct quantitative validation in vivo. Although our in vivo data concurrently demonstrated an increase in M2 macrophages and the most significant bone regeneration outcomes in the CGF/PP@MN group, the current study has not performed a statistical correlation analysis within the same animal model between the precise phenotypes of immune cells at the defect site (e.g., quantified via flow cytometry) and the expression levels of osteogenic markers or neobone structural parameters. Consequently, the contributory role of M2 polarization as the central bridge mediating the superior osteogenic performance of the material in vivo warrants final confirmation through more refined in vivo tracking and quantification techniques in future work (e.g., spatiotemporally correlating immune cell subsets analyzed by flow cytometry with bone formation parameters from micro‐CT/histomorphometry). Elucidating this quantitative in vivo relationship will be key to consolidating the mechanistic foundation of this therapeutic strategy. Recently, advanced strategies have emerged that harness dynamic material–host interactions to achieve sequential regulation of the wound microenvironment. For example, Tang et al. developed a microenvironment‐feedback hydrogel that enables precise, stage‐adaptive repair of acute infectious wounds through the synergistic actions of tannic acid (TA) and bioactive glass (BAG) [99]. In their system, TA scavenges reactive oxygen species (ROS), blocks the NF‐κB signaling pathway, and promotes M2 macrophage polarization, while ions released from BAG (such as Zn2 + and Ca2 +) further enhance angiogenesis and tissue remodeling. Similarly, electrospun fiber‐based immune engineering has been demonstrated to modulate immune responses through strategies including surface modification, drug loading, physicochemical parameter tuning, and biological grafting [100]. These reports underscore the importance of orchestrating a shift from a pro‐inflammatory to a pro‐regenerative immune microenvironment. Inspired by these concepts, our material can in future studies be further validated for sequential immunomodulation following similar experimental designs, as supported by our in vitro data on ROS scavenging, M1‐to‐M2 polarization, and in vivo wound healing outcomes. Although direct in vivo time‐course immune profiling is currently lacking, the mechanistic parallels with these established strategies support our proposed hypothesis of “immune remodeling‐driven osteogenesis.” It is important to acknowledge the limitations of the present study. The critical‐sized calvarial defect model in diabetic rats, while a well‐validated system for preliminary evaluation of osteogenic efficacy, is a non‐load‐bearing model. Although it successfully demonstrated the capacity of the CGF/PP@MN system to counteract diabetic pathophysiological barriers and stimulate robust bone regeneration, the healing of load‐bearing skeletal defects presents distinct and more complex challenges. These include the requirement for sufficient initial mechanical support to stabilize the defect site, the need for rapid and extensive vascularization to supply larger tissue volumes, and the subsequent remodeling of the regenerated bone to achieve biomechanical competence under physiological stress. Future investigations employing load‐bearing defect models in diabetic animals (e.g., in femurs or tibiae) will be essential to evaluate the system's performance in this more clinically relevant and demanding context, particularly its integration with mechanical stabilization strategies and its ability to orchestrate healing under dynamic loading conditions. Furthermore, from a clinical translation perspective, the stability of the loaded bioactive components—particularly the responsive peptides and the proteinaceous growth factors within CGF—during long‐term storage and after implantation is crucial for ensuring reproducible efficacy and successful product commercialization. Future formulation development may explore strategies including, but not limited to, the incorporation of cryoprotectants or lyophilization during manufacturing to enhance storage stability, rational structural modification of the peptides (e.g., incorporation of D‐amino acids or cyclization) to improve their enzymatic stability, or secondary encapsulation techniques (e.g., microencapsulation) to provide an additional protective barrier for microenvironment‐sensitive growth factors. These approaches aim to ultimately yield a next‐generation product that combines efficient, intelligent release with excellent shelf‐life and in vivo stability. Conclusion In summary, we have engineered and rigorously validated a compartmentalized, stimuli‐responsive microneedle array that actively coordinates immune modulation, antimicrobial defense, and osteogenic regeneration for treating diabetic bone defects. The therapeutic success of this system is defined by a composite of key outcomes: the achievement of near‐complete closure of a critical‐sized defect (BV/TV ∼64.5%) within 8 weeks, the regeneration of highly mineralized (BMD ∼0.72 g/cm3), mature lamellar bone, and the establishment of a pro‐healing molecular and cellular milieu characterized by M2 macrophage polarization, active angiogenesis, and sustained osteogenic activity. The core advance of this work is the establishment of a spatiotemporally programmable platform that transitions regenerative therapy from a static, one‐dimensional delivery paradigm to a dynamic, multi‐stage therapeutic program. The system's intelligent responsiveness to pathological signals (GSH/MMP‐2/9) ensures precise, on‐demand bioactivity, while its compartmentalized design ensures the correct therapeutic agent is deployed at the optimal time and location, effectively mirroring the endogenous sequence of bone repair. Through comprehensive evaluation, we have demonstrated that this temporally coordinated strategy yields synergistic, hierarchically superior outcomes, effectively breaking the vicious cycle of infection and inflammation that characterizes diabetic healing. Beyond introducing a potent device for a specific clinical challenge, this work proposes a generalizable framework for next‐generation smart biomaterials—one defined by environmental awareness, temporal control, and functional coordination. It highlights that the synchronization of immune and osteogenic processes is not merely beneficial but essential for regeneration in hostile microenvironments. This platform, therefore, represents a step toward truly adaptive regenerative medicine, with potential applicability to a broad range of complex tissue healing scenarios where sequential, multi‐modal intervention is required. Future development should focus on scalability, long‐term biocompatibility, and integration with patient‐specific factors, paving the way for intelligent, personalized tissue engineering solutions. Experimental Section Synthesis and Purification of Peptides pro‐AMP and pro‐AIP were synthesized and purified by Qiangyao Biological Co., Ltd. (China). Specifically, the peptides were synthesized from the C‐terminus to the N‐terminus via solid‐phase peptide synthesis. Initially, n equivalents of resin were swelled in dichloromethane (DCM) for 30 min, after which the DCM was removed. The first amino acid (2n eq.) and diisopropylethylamine (DIEA, 2n eq.) were dissolved in a mixture of dimethylformamide (DMF) and DCM—added in amounts sufficient to ensure efficient resin agitation—and reacted under nitrogen bubbling for 60 min. Methanol (5n eq.) was then introduced to cap any unreacted sites, and the mixture was agitated for an additional 30 min. The resin was subsequently washed sequentially with DMF and methanol. The subsequent amino acid (2n eq.) was coupled using HBTU (2n eq.) and DIEA under a nitrogen atmosphere for 30 min. After draining the reaction mixture and washing the resin, a Kaiser test was performed to confirm coupling completion. Any remaining free amines were acetylated using a mixture of pyridine and acetic anhydride. Following washing, the Fmoc protecting group was cleaved with a dedicated deblocking solution, and resin washing was repeated. A further Kaiser test was conducted to verify Fmoc removal. This iterative process—coupling, capping, deprotection, and confirmation—was repeated for each subsequent amino acid and incorporated modification throughout the sequence. Upon completion of the synthesis, the resin was dried under nitrogen, transferred to a cleavage vessel, and treated with a cleavage cocktail (95% TFA, 2% ethanedithiol, 2% triisopropylsilane, 1% water; approx. 10 mL per gram of resin) under agitation. The resin was then filtered off, and the peptide was precipitated from the filtrate by the addition of cold diethyl ether. The crude product was isolated via centrifugation and washed. Purification was carried out using high‐performance liquid chromatography (HPLC) to achieve the desired purity. The purified peptide solution was concentrated and lyophilized, yielding the final product as a white powder. Preparation of GelMA Twenty grams of gelatin were dissolved in 200 mL of PBS and allowed to swell for 3 h. The swollen gelatin was then stirred in a 60 °C water bath under protection from light until complete dissolution was achieved. Subsequently, 16 mL of methacrylic anhydride (MA) was added dropwise at a rate of 0.25 mL/min using a syringe pump, and the reaction was continued for 2 h with stirring. The reaction was terminated by adding 800 mL of PBS. The resulting GelMA solution was transferred into dialysis bags and dialyzed against deionized water under stirring, followed by freeze‐drying to obtain the purified GelMA solid. Extraction of Concentrated Growth Factors Venous blood (8 mL) was collected from SD(Sprague Dawley) rats using blood collection tubes without anticoagulants and immediately processed in a specialized centrifuge (Medifrade MF200; Silfradent srl, Forlì, Italy) to obtain concentrated growth factors (CGF). According to the manufacturer's protocol, each blood sample was centrifuged for 13 min using the following sequential protocol: 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, and 3 min at 3000 rpm. This centrifugation procedure yielded three distinct fractions: a top serum layer, a middle fibrin‐rich layer containing high concentrations of CGF, and a bottom layer consisting of red blood cells and platelets. The upper serum layer was carefully decanted, while the middle fibrin layer, along with the adjacent red blood cell layer—representing the CGF gel—was retained intact for further use. Quantification of TGF‐β1 as a Representative Component of CGF The concentration of TGF‐β1, used as a representative proxy for Concentrated Growth Factor (CGF) content, was quantified using a commercially available enzyme‐linked immunosorbent assay (ELISA) kit (Rat TGF‐β1 ELISA Kit, Jiangsu Jingmei Biological Technology Co., Ltd., China; Lot No. 2312C85; Cat# JM‐11507R1) according to the manufacturer's instructions. Briefly, samples and standards were added to antibody‐precoated microwells. After incubation and washing, horseradish peroxidase (HRP)‐conjugated detection antibody was introduced. A colorimetric reaction was initiated by the addition of tetramethylbenzidine (TMB) substrate and terminated with sulfuric acid. The absorbance was measured at 450 nm using a microplate reader. A standard curve was constructed from known concentrations of TGF‐β1 standards (0–32 pg/mL), and sample concentrations were interpolated from the curve. All samples were analyzed in duplicate, and the mean values are reported. The kit performance was validated as follows: Accuracy: The correlation coefficient (R) between the linear regression of standards and expected concentrations was ≥0.9900. Sensitivity: The minimum detectable concentration was <1.0 pg/mL. Detection range: 1.0 – 32 pg/mL. Specificity: No cross‐reactivity with other soluble structural analogs. Repeatability The intra‐assay and inter‐assay coefficients of variation were both <15%. Preparation of microneedles patch. The microneedles were fabricated using a 12 × 12 array polydimethylsiloxane (PDMS) mold, with each needle measuring 800 µm in height and 200 µm in width at the base. A 10% (w/v) GelMA‐60 hydrogel precursor solution was blended with concentrated growth factors (CGF) at a concentration of 100 mg/mL, and photoinitiator (PI) was added at a concentration of 0.5%. The resulting mixture was infused into the mold cavities. Degassing was performed under vacuum at 35°C in a water bath, repeated two to three times until no air residues remained in the needle tips. The first drying and concentration step was conducted in an oven at 30–35°C for approximately 5–6 h until a viscous consistency was attained. A second aliquot of the blended solution was then added, and a second concentration step was carried out under identical heating conditions for an additional 5–6 h. Photo‐crosslinking was induced by exposure to UV light at 405 nm. The microneedles were subsequently dried in an oven at 30–35°C for more than 12 h. After thorough drying, the structures were carefully demolded using tweezers. For surface functionalization, the cured blank GelMA microneedle patches were immersed in phosphate‐buffered saline (PBS, pH 7.4) containing pro‐AMP (200 µg/mL) and pro‐AIP (200 µg/mL) and incubated at 4°C for 12 h in the dark. The patches were then removed and dried at room temperature under sterile conditions. The actual loading amount of each peptide was determined to be approximately 100 ± 10 µg per patch by the weight difference method, corresponding to a loading efficiency of approximately 50%. The actual loading amount of concentrated growth factors (CGF) was 100 mg per patch. Characterization of Microneedles Patch The morphological characteristics of the microneedles, including needle integrity, tip shape, and surface texture, were evaluated using optical microscopy and scanning electron microscopy (SEM; ZEISS Gemini300, Germany). Prior to SEM imaging, samples were sputter‐coated with a thin layer of gold to enhance conductivity. For compositional and structural analysis, Fourier transform infrared spectroscopy (FTIR) was performed to identify functional groups and molecular interactions within the GelMA matrix and composite formulations. X‐ray diffraction (XRD) was employed to investigate the crystallinity and phase composition of the samples. Additionally, x‐ray photoelectron spectroscopy (XPS) was conducted to analyze the surface elemental composition and chemical states of both pure GelMA and the modified microneedle patches. All spectral data were collected under consistent operational settings, and subsequent analyses were performed to correlate physicochemical properties with functional performance. In Vitro Drug Release To evaluate the in vitro release kinetics of two peptides from microneedle patches, LC–MS/MS was employed to quantify peptide concentrations at predetermined time intervals. The experimental groups consisted of: a blank control (PBS buffer only), glutathione (GSH) treatment groups (20 and 200 µm), and gelatinase treatment groups (1 and 10 µm). The peptide‐loaded microneedles were incubated in the respective solutions under gentle agitation at 37°C. Supernatants were collected at 0.5, 1, 2, 6, 12, and 24 h, followed by centrifugation at 15,000 rpm for 10 min at 4°C (Centrifuge 5430 R, Eppendorf, Germany). The resulting supernatant was subjected to LC–MS/MS analysis. Analysis was performed using an AB6500+ triple quadrupole mass spectrometer coupled with an EXIONLC AD UHPLC system (Sciex, USA). Chromatographic separation was achieved on a Waters BEH C18 column (1.7 µm, 2.1 × 50 mm) maintained at 40 °C. The mobile phase consisted of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B), delivered at a flow rate of 0.30 mL/min with the following gradient program: 0–1.5 min, 20% → 50% B; 1.5–2.0 min, 50% → 100% B; 2.0–2.5 min, 100% B; 2.5–2.6 min, 100% → 20% B; and 2.6–4.0 min, 20% B. The injection volume was 5 µL. Mass spectrometric detection was conducted in positive electrospray ionization (ESI) mode using multiple reaction monitoring (MRM). The ion spray voltage was set to 5500 V, and the source temperature was 550 °C. Curtain gas (CUR), nebulizing gas (Gas 1), and turbo gas (Gas 2) were set to 35, 45, and 45 psi, respectively. The MRM transitions used for quantification were 581 → 478.8 and 751.7 → 152.1. A calibration curve spanning 0.2–200 ng/mL was established for each peptide, and all samples were analyzed in triplicate. Mechanical Testing The mechanical strength of the hydrogel microneedles was evaluated using a universal mechanical testing system (CMT6103, Sans, China). The microneedle patch was horizontally positioned on the stationary platform of the tester. A compressive load was applied uniformly to the tips of the microneedles at a constant displacement rate of 0.5 mm/min until either fracture or complete deformation occurred, simulating the skin insertion process. The force‐displacement curves were recorded in real time, and the mechanical behavior was analyzed based on the maximum fracture force and deformation energy. Data were processed and visualized using Origin 2022 software to generate compressive stress‐displacement profiles. Cytotoxicity Assay The cytotoxicity of material extracts on RAW264.7 macrophages was evaluated using the Cell Counting Kit‐8 (CCK‐8) assay. RAW264.7 cells were seeded in 96‐well plates at a density of 8 × 103 cells per well and co‐cultured for 24 h with material extracts from the following groups: Control (PBS), MN (blank microneedles), PP@MN (microneedles loaded with Pro‐AMP@Pro‐AIP), CGF@MN (CGF‐loaded microneedles), and CGF/PP@MN (microneedles loaded with CGF/Pro‐AMP@Pro‐AIP), with concentrations ranging from 0 to 500 µg/mL. Following incubation, 10 µL of CCK‐8 reagent was added to each well, and the plates were further incubated for 2.5 h. The absorbance at 450 nm was measured using a microplate reader. The relative cell viability was calculated using the formula: (OD value of the experimental group / OD value of the control group) × 100%. Each concentration was tested with six replicate wells, and the experiment was independently repeated three times. Live/Dead Staining A Live/Dead double‐staining assay was performed using Calcein‐AM and Propidium Iodide (PI) to visually assess the cytocompatibility of the materials with both RAW264.7 cells and bone marrow mesenchymal stem cells (BMSCs). After the designated co‐culture period with material extracts, cells were stained with a working solution containing 2 µM Calcein‐AM and 4.5 µM PI, followed by incubation at 37°C in the dark for 30 min. After gentle washing with PBS, the cells were immediately observed under a laser scanning confocal microscope. Viable cells (with intact esterase activity) fluoresced green, while dead cells (with compromised membrane integrity) fluoresced red. Representative images were captured for analysis. In Vivo Histocompatibility Major organs (heart, liver, spleen, lung, kidney) were collected from SD rats (male, 250±20 g). The tissues were fixed in 4% paraformaldehyde for 36 h, dehydrated through a graded ethanol series, embedded in paraffin, and sectioned into 4 µm thick slices. Hematoxylin and eosin (H&E) staining was performed to observe tissue morphology and inflammatory cell infiltration. A semi‐quantitative histopathological scoring system was used for evaluation. Colony Formation Assay Staphylococcus aureus(S. aureus ATCC 25923) and Escherichia coli(E. coli ATCC 25922) were inoculated in LB liquid medium and cultured to the logarithmic growth phase (OD600≈0.8). The bacterial suspension was adjusted to 5×106 CFU/mL and co‐cultured with the material groups. After 24 h of culture, ten‐fold serial dilutions were performed, and 50 µL of the diluted solution was spread on LB agar plates. The plates were incubated inverted at 37°C for 20 h, and colony‐forming units (CFUs) were counted. The experiment included three independent biological replicates. Bacterial Live/Dead Staining A 2 mL bacterial suspension was centrifuged and resuspended in PBS, followed by the addition of SYTO 9 (final concentration 8 µM) and PI (final concentration 35 µm). After incubation at room temperature in the dark for 20 min, 15 µL of the bacterial suspension was placed on a glass slide for observation under a confocal microscope (Leica TCS SP8). SYTO 9 excitation wavelength was 480 nm (emission: 500 nm), and PI excitation wavelength was 490 nm (emission: 635 nm). Fluorescence intensity ratios were analyzed using LAS X software. Bacterial Transcriptomic Sequencing In this study, a comprehensive transcriptomic analysis of Staphylococcus aureussubsp. aureusNCTC 8325 was conducted. Total RNA was extracted from samples, sequencing libraries were prepared, and paired‐end sequencing was performed on the Illumina platform. Raw sequencing data underwent stringent quality control, with an average sequencing depth of approximately 3.01 Gb. Adapter and low‐quality sequences were filtered using Fastp, yielding high‐quality data with average Q20 and Q30 scores exceeding 99.6% and 98.5%, respectively, and GC content ranging from 38.2% to 47.2%. High‐quality reads were aligned to the reference genome using Bowtie2, with alignment rates varying between 20.07% and 60.36%. Gene expression was quantified using featureCounts and normalized by FPKM. Differential expression analysis was performed with DESeq2, applying thresholds of |log2(fold change)| > 1 and an FDR‐adjusted p‐value < 0.05. Functional annotation of genes against databases including GO, KEGG, NR, Swiss‐Prot, and KOG was carried out using EggNOG‐mapper and DIAMOND, followed by over‐representation and gene set enrichment analyses of differentially expressed genes. Furthermore, a suite of advanced bioinformatic analyses was integrated: Weighted Gene Co‐expression Network Analysis (WGCNA) was employed to identify co‐expressed gene modules and their association with phenotypic traits; variant calling (SNPs and InDels) and annotation were performed using bcftools and SnpEff; transcriptomic features such as transcription start/termination sites, untranslated regions, and operon structures were predicted using Rockhopper; secondary structures of predicted small non‐coding RNAs were modeled with ViennaRNA; and a protein‐protein interaction network was inferred based on the STRING database. This multifaceted analytical workflow systematically characterized the bacterial transcriptomic landscape, encompassing gene expression dynamics, functional enrichment, regulatory elements, genomic variation, and potential molecular interaction networks. Sequencing depth: The average data output per sample was 3.01 Gb. Mapping rate: The genome mapping rate ranged from 20.07% to 60.36% across all six samples. Establishment of Cranial Infection Model and Assessment of In Vivo Antibacterial Efficacy Male Sprague‐Dawley rats were anesthetized, and two critical‐sized defects, each 5mm in diameter, were created bilaterally along the midline of the skull. A methicillin‐resistant Staphylococcus aureus(MRSA) suspension (1 × 108 CFU/mL) was inoculated into the defect sites to establish an infection model, after which differently treated microneedle patches were implanted. On postoperative day 7, the animals were euthanized, and cranial samples were collected for a multi‐dimensional assessment of antibacterial efficacy. The bone tissue samples were divided into three parts for systematic evaluation using the following methods: crystal violet staining (absorbance measured at 570 nm to quantify biofilm biomass), colony counting assay (gradient dilution and plate culturing of homogenates to calculate colony‐forming units per milligram of tissue for assessing viable bacterial load), and Gram staining (standard staining of decalcified paraffin sections to observe bacterial colonization and histopathological changes under an optical microscope). These approaches collectively analyzed the comprehensive antibacterial effects of different microneedle formulations in terms of biofilm eradication, bacterial killing, and improvement of tissue pathology. Immunofluorescence Staining and Quantitative Analysis To evaluate the effect of the materials on macrophage polarization, the RAW 264.7 cell line was used. Following intervention with different materials, cells were subjected to immunofluorescence staining. Cells were fixed with 4% paraformaldehyde and sequentially incubated with primary antibodies (anti‐iNOS, anti‐CD206) at 4°C overnight, followed by incubation with corresponding Alexa Fluor‐conjugated secondary antibodies and DAPI for nuclear staining. Images were observed and captured using a confocal microscope (Figure 6A,B). The fluorescence intensity (Figure 6C,D) and the proportion of positive cells (Figure 6E,F) for iNOS (an M1 phenotype marker) and CD206 (an M2 phenotype marker) were quantified using ImageJ software. Quantitative Real‐Time PCR To validate macrophage phenotype at the gene expression level, total RNA was extracted from treated RAW 264.7 cells using the TRIzol method. After concentration and purity assessment, 1 µg of RNA was reverse‐transcribed into cDNA using the PrimeScript RT reagent Kit. Amplification was performed on a real‐time PCR system using the SYBR Premix Ex Taq II kit. Genes analyzed included M1‐associated markers (iNOS, IL‐1β, TNF‐α) and the M2‐associated marker (Arg‐1). GAPDH was used as the internal reference gene, and the relative expression of target genes was calculated using the 2−ΔΔCt method (Figures 6G‐I and 7E‐G). Flow Cytometric Analysis of Macrophage Phenotype To quantitatively assess the effect of materials on M1/M2 macrophage polarization, the expression of surface markers CD86 (M1 phenotype) and CD206 (M2 phenotype) was analyzed by flow cytometry. After co‐treatment with LPS (200 ng/mL) and different materials for 36 h, RAW 264.7 cells were collected and dissociated into single‐cell suspensions using trypsin. Cells were washed twice with ice‐cold PBS and subsequently incubated with fluorophore‐conjugated anti‐mouse CD86 and anti‐mouse CD206 antibodies at 4°C in the dark for 30 min. Following incubation, unbound antibodies were removed by washing with PBS containing 2% FBS, and cells were finally resuspended in an appropriate volume of PBS. Detection was performed using a flow cytometer (e.g., BD FACSVerse), collecting at least 10,000 events per sample. Data were analyzed with FlowJo software. The distribution of M1 and M2 phenotypes within the macrophage population was quantitatively evaluated by comparing the ratios of CD86‐positive to CD206‐positive cells across different groups. Alkaline Phosphatase (ALP) Activity and Staining Bone marrow mesenchymal stem cells (BMSCs) were cultured under the influence of different material groups. ALP activity, an early marker of osteogenic differentiation, was assessed quantitatively using a commercial kit. In parallel, cells were fixed and stained using a BCIP/NBT substrate solution to visualize ALP enzymatic activity, as depicted in Figure 8A. Alizarin Red S Staining To evaluate late‐stage matrix mineralization, BMSCs were cultured for 21 days. Cells were then fixed and stained with 0.1% Alizarin Red S solution (pH 4.1) to detect calcium deposits. The stained mineralized nodules were observed microscopically (Figure 8A, top rows). For quantification, the bound dye was dissolved with 10% cetylpyridinium chloride, and the absorbance was measured at 570 nm (Figure 8C). Western Blot Analysis After 14 days of osteogenic induction, total protein was extracted from BMSCs. The expression levels of key osteogenic proteins, including Runt‐related transcription factor 2 (Runx‐2), Collagen type I alpha 1 (COL1‐a1), and Osteopontin, were analyzed by western blot. β‐actin was used as a loading control. Representative blots are shown in Figure 8B, and the corresponding densitometric quantifications are presented in Figure 8E‐G. Quantitative Real‐Time PCR (qPCR) Total RNA was extracted from BMSCs, reverse‐transcribed into cDNA, and analyzed via qPCR using SYBR Green kits. The expression of osteogenic genes, including Runx2, Col1a1, and Osteopontin, was quantified. GAPDH served as the internal reference control. Diabetict Calvarial Defect Model. All animal experiments were approved by the Ethics Committee of Soochow University. The experimental protocols were reviewed and authorized by the Institutional Animal Care and Use Committee of Soochow University. All procedures were conducted in accordance with relevant guidelines and regulations. Male Sprague‐Dawley (SD) rats, 6 weeks old, were fed a high‐sugar and high‐fat diet for one month. Diabetes was induced via intraperitoneal injection of streptozotocin (STZ; Sigma‐Aldrich) dissolved in citrate buffer (pH 4.5) at a dose of 60 mg/kg. Rats with sustained blood glucose levels exceeding 16.7 mmol/L were considered diabetic and were randomly assigned to five groups (n = 10 per group): control, GelMA microneedle (MN) patch, peptides@MN patch (PP@MN), CGF@MN patch (CGF@MN), and peptides@CGF MN patch (CGF/PP@MN). Under anesthesia with 1.5% sodium pentobarbital and under strict aseptic conditions, two critical‐sized calvarial defects with a diameter of 5 mm were created in each rat using a dental drill. The corresponding microneedle patches were implanted into the defect sites. At predetermined intervals (4 and 8 weeks post‐implantation), the rats were euthanized by CO2 asphyxiation, and calvarial bone samples were harvested for further analysis. No signs of pain or distress were observed during or after the surgical procedures or throughout the study period. Micro‐Computed Tomography (Micro‐CT) Following fixation, all specimens were subjected to micro‐computed tomography (µCT) scanning using a Skyscan 1272 scanner (Bruker MicroCT, Germany). The scanning parameters were set as follows: x‐ray tube current 200µA, voltage 85kV, exposure time 240 ms per projection, with a 180‐degree rotation at an isotropic resolution of 9.064026µm. A manufacturer‐supplied phantom was scanned under identical conditions for calibration. The acquired raw projection data were subsequently reconstructed using the NRecon software (Version V1.7.4.2, Bruker MicroCT, Germany). To minimize artifacts and optimize reconstruction quality, key parameters were adjusted, including a Smoothing of 5, a Beam‐hardening correction of 8, and a Ring artifact reduction of 25%. Following parameter configuration, a preview was conducted, and the reconstruction was performed on the selected volume of interest. Subsequent morphometric analysis was carried out on the reconstructed images using CT Analyzer software (Version 1.20.3.0, Bruker MicroCT, Germany). A standardized volume of interest (VOI) was defined for all samples, from which the software calculated parameters including tissue volume (TV), bone volume (BV), bone volume fraction (BV/TV), bone surface (BS), trabecular number (Tb.N), and trabecular thickness (Tb.Th). Histological Analysis The calvarial specimens were decalcified in 10% ethylenediaminetetraacetic acid (EDTA; Sigma‐Aldrich) for approximately one month, embedded in paraffin, and sectioned into 6 µm‐thick slices. Sections were stained with hematoxylin and eosin (H&E) and Masson's trichrome for general morphological evaluation and collagen deposition analysis. At 2 weeks post‐implantation, major organs (heart, liver, spleen, lungs, and kidneys) were harvested from both the experimental group (implanted with CGF/PP@MN composites) and the control group (sham‐operated). Tissue sections were prepared and subjected to hematoxylin and eosin (H&E) staining to evaluate potential systemic toxicity or immune responses. Histopathological analysis focused on assessing structural integrity, inflammatory cell infiltration, and abnormal morphological changes in each organ. This systemic safety assessment aimed to determine the biocompatibility and biosafety profile of the implanted materials. Quantitative analysis of immunohistochemical staining was conducted using image analysis software. Immunohistochemical and immunofluorescence assays for osteogenic markers (OCN and OPN) were performed at 4 and 8 weeks to evaluate bone repair. Diabetic Wound Healing Model The diabetic rats were randomly divided into five groups (n = 10 per group): control, GelMA microneedle (MN) patch, GelMA@peptides MN patch (PP@MN), GelMA@CGF MN patch (CGF@MN), and GelMA@peptide+CGF MN patch (CGF/PP@MN). Rats were anesthetized by intraperitoneal injection of 0.3% sodium pentobarbital (0.1 mL/10 g body weight). A full‐thickness skin wound measuring 10 mm in diameter was excised along the dorsal midline. Wounds were covered with PBS, GelMA MNs, GelMA@peptides MNs, GelMA@CGF MNs, or GelMA‐peptides+CGF MNs (Figure S10A,B). Digital photographs were taken on days 0, 3, 7, 11, and 14 post‐wounding. Wound areas were measured and quantified using ImageJ software. Histological Staining. On day 14, wound tissue samples were harvested and cut into 10 mm × 12 mm strips. Mechanical testing was performed using a universal testing machine equipped with a 50 N load cell at a crosshead speed of 1 mm/min. Skin specimens containing the wound area were fixed in 4% paraformaldehyde for 48 h, dehydrated, and embedded in paraffin. Serial sections of 5 µm thickness were obtained using a microtome and stained with hematoxylin and eosin (H&E) (Figure S11). Images were captured using a fluorescence microscope and analyzed with ImageJ software. Statistical Analysis Data were statistically analyzed using unpaired Student's t‐test and one‐way analysis of variance (ANOVA) for multiple comparisons. A p‐value of less than 0.05 was considered statistically significant. All analyses were performed using Origin 2022 software. Data are presented as mean ± standard deviation (SD) from three independent experiments. Author Contributions Y.W. designed the study, performed the experiments, collected and analyzed the data, and wrote the original draft. R.C. was responsible for material preparation and characterization, conducted in vitro experiments, and curated the data. Y.C. assisted with material synthesis, performed part of the physicochemical characterization, and contributed to data validation. H.L. and Y.Q. performed cell culture experiments and assisted in functional assays. Z.G. carried out statistical analysis and contributed to figure preparation. Z.S. provided technical support in microscopy imaging and data acquisition. J.Z. and X.Z. conceived the study, reviewed, and edited the manuscript. H.Y. provided related resources, assisted in data interpretation, and revised the manuscript. Y.Q. performed bioinformatics analysis, visualized the data, and participated in manuscript revision. Funding This work was supported by the National Natural Science Foundation of China (Grant No. 82572432) and the China Postdoctoral Science Foundation (Grant No. 2025M782211). Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File: adma73803‐sup‐0001‐SuppMat.pdf. Acknowledgements The authors acknowledge the technical support and valuable suggestions provided by the experts at Soochow University. We also express our gratitude to all colleagues and collaborators for their assistance in experimental design and data analysis. Contributor Information Huilin Yang, Email: suzhouspine@163.com. Jun Zou, Email: jzou@suda.edu.cn. Yusen Qiao, Email: qiaoyusen8612@suda.edu.cn. Data Availability Statement The data that support the findings of this study are available in the supplementary material of this article. References Associated Data Supplementary Materials Supporting File: adma73803‐sup‐0001‐SuppMat.pdf. Data Availability Statement The data that support the findings of this study are available in the supplementary material of this article.